>>WE'RE GOING
TO TRANSITION NOW TO OUR OPEN
SESSION.
THIS SESSION IS AGAIN
VIDEOCAST SO MEMBERS OF THE
PUBLIC WILL BE ABLE TO VIEW
THIS PARTICULAR PART OF THE
SESSION.
WE HAVE -- BEFORE I TURN IT
OVER TO Dr. HODES TO START
US OFF, I JUST LIKE TO DO A
QUICK ROLL CALL OF OUR COUNCIL
MEMBERS.
AND AS I CALL YOUR NAME, IF
YOU COULD PLEASE JUST GIVE
YOUR FULL NAME AND AFFILIATION
AND FOR THE BENEFIT OF THOSE
LISTENING ONLINE.
ALL RIGHT.
SO YOU CAN START OFF WITH
Dr. ASANA.
>>SA NJE ASANA FROM WISCONSIN
IN MANAGEMENT.
>>DOCTOR BAKER?
>>MAYO CLINIC --
[INDISCERNIBLE]
>>Dr. KING?
>>ANN KING, PRINCE TON
UNIVERSITY.
>>AND Dr. PHILIBERTO?
>>CAREGIVER AND FAMILY
REPRESENTATIVE.
>>Dr. CRUZ?
[INAUDIBLE]
>>Dr. HOLONG IS NOT PRESENT
TODAY, REVEREND DOCTOR HUMMEL.
>>CYNTHIA HUMM ENGINE L,
REPRESENTING THOSE LIVING WITH
ALZHEIMER'S AND RELATED
DEMENTIAS.
>>Dr. INOUE?
>>YES, Dr. INOUE, HARVARD
MEDICAL SCHOOL, MASSACHUSETTS.
>>Dr. CAHN?
[INAUDIBLE]
>>THANK YOU, Dr. LONGO?
>>FRANK LONGO, DEPARTMENT OF
AOURLG, STANFORD UNIVERSITY.
>> Dr. LUNDEBERG?
>>Dr. LUNDEBERG --
[INAUDIBLE].
>>Dr. PETERSON?
[INAUDIBLE]
>>Dr. RUBEN?
>>DAVID RUBEN, SCHOOL OF
MEDICINE AT UCLA.
>>Dr. SNYDER?
>>FELIX SCHNEIDER, UNIVERSITY
MEDICAL CENTER.
>>AND ONLINE WE HAVE DAVID
WEIR?
>>DAVID WEIR, UNIVERSITY OF
MICHIGAN.
>>ALL RIGHT, AND I THINK
THAT'S -- OH, I AM SORRY,
LINDA.
>>LINDA VANELL, UNIVERSITY OF
KENTUCKY.
>>SUSAN GREEN SPOILED SPAN,
UNIVERSITY OF PITTSBURGH.
>>APOLOGIES FOR THAT.
OKAY TO THIS OFFICIALLY STARTS
THEN OUR OPEN SESSION OF THE
149TH NATIONAL ADVISORY
COUNCIL ON AGING AND I WOULD
LIKE TO WELCOME EVERYONE AND
TURN THE MEETING OVER TO OUR
CHAIR, Dr. RICHARD HODES.
>>WELL, WELCOME ALL TO THE
OPEN SESSION OF OUR COUNCIL.
AS ALWAYS, I WILL GO THROUGH A
VERY BRIEF SET OF HIGHLIGHTS
OF WHAT IS HAPPENING BUT ALSO
GIVE YOU THE OPPORTUNITY TO
ASK ANY QUESTIONS YOU HAVE GOT
BEFORE WE TURN TO THE REST OF
OUR AGENDA.
NEXT SLIDE, PLEASE.
EACH YEAR UPDATE ON BUDGET AND
SPENDING FOR COUNCIL, NEXT.
WHAT IS NEW THIS YEAR SINCE
OUR LAST SESSION WHEN WE HAD
OUR BUDGET APPROPRIATIONS IS
THE REVISION AND SETTING OF
OUR PAY LINES AS YOU CAN SEE
HERE.
IN THE CSR REVIEWED
APPLICATIONS, THOSE OF A
PERCENTILE THEREFORE, THE
GENERAL PAYLINE FOR THE MOST
COMMON APPLICATIONS UNDER
$500,000 DIRECT COST, THE
15 PERCENT PERTILE IS AT
THRESHOLD AND THIS IS
RELATIVELY GOOD FOR PAST
YEARS, HOPEFULLY WE CAN EVEN
DO BETTER.
THESE ARE NOT FINAL BECAUSE WE
HAVE MORE TIME IN THE YEAR TO
SEE HOW THINGS EVOLVE AND MAKE
REF OCCASIONS TO FUNDING
LEVELS.
WE REMAIN COMMITTED TO NEW
INVESTIGATORS IN AI AND NI,
YOU CAN SEE THERE THE 20TH
PERCENTILE FROM THE GENERAL
PAYLINE, MORE EXPENSIVE AT
$500,000, ALWAYS A PAINFUL
DISCRIMINATION BUT ONE WE IN
LIST TO IN ORDER TO PROTECT
OUR OVERALL PAYLINE, A HIGHER
BAR FOR THOSE APPLICATIONS AT
12TH PERCENTILE BUT THOSE ARE
FOR NEW AND EARLY STAGES
INVESTIGATOR.
AND EACH YEAR, IN FACT SEVERAL
PAST YEARS, WE HAVE HAD A PA
HIGHER PAYLINE IN ALZHEIMER'S
AND DEMENTIA RESEARCH DUE TO
APPROPRIATIONS FROM CONGRESS.
THIS YEAR WE'RE AT THE 25TH
PERCENTILE FOR THE FALL
APPLICATIONS EXCEPT THE NA --
[INDISCERNIBLE]
-- IN 20TH PERCENTILE.
NEXT, PLEASE.
FOR THE NIA REVIEWED
APPLICATIONS YOU CAN SEE HERE
ONCE AGAIN PROGRAM PROJECTS
AND OTHER RESEARCH, 24TH
PRIORITY SCORE, CAREER
DEVELOPMENT, 24, DEVELOPMENT
IS 30 AGAIN WITH HIGHER PAY
LINES FOR EACH OF THESE AS
ALLOWED WITH THE FUNDING
AVAILABLE.
AS PART OF OUR COMMITMENT TO
USING APPROPRIATED FUNDS THAT
ARE ADARL TARGETED, WE ARE
REGARDED AS OUR OBLIGATION AND
STRATEGY FOR BEST UTILIZING
OUR FUNDED GOALS ACROSS ALL OF
NIH, YOU CAN SEE HERE YEAR
AFTER YEAR THE AMOUNTS THAT
HAVE BEEN GIVEN FROM NIA
APPROPRIATED FUNDS TO SUPPORT
RESEARCH AND YOU CAN SEE FY22,
THE LAST YEAR FOR WHICH WE
HAVE ANY FREE DATA, THIS
WAS -- FOR THE TOTAL YEAR,
NEARLY ALL OF THE SISTER
INSTITUTIONS, NIDS, THE
PRIMARY PARTNERS YOU CAN SEE
ACROSS EACH OF THESE
INSTITUTES, SUBSTANTIAL
FUNDING.
ONE DIMENSION USED THROUGH
FUNDING SUPPLEMENTS THAT ARE
ADRD RELEVANT THROUGH
APPLICATIONS FOR THEMSELVES
AND DID NOT ORIGINATE WITH THE
PRIMARY APPLICATION AND I
THINK THAT HAS BEEN SUCCESSFUL
IN RECRUITING NEW TALENT IN
RESEARCH AND AS WE LOOK AT
THAT PROGRAM, WE SEE A
SUBSTANTIAL NUMBER OF
INDIVIDUALS TURNING TO SUPPORT
ALZ-'S RESEARCH AS A PRIMARY
IN THAT AREA SO IT HAS BEEN
VERY SUCCESSFUL FOR THOSE
PEOPLE.
NEXT PLEASE.
THE SAME LINE, WE HAVE LOOKED
AT WHERE OUR RESEARCH
APPLICATIONS AND FUNDING ARE
GOING AND OVER THE YEARS FROM
2015 TO 2022, THE YEARS HAVE
INCREASED TARGETED FUNNELING
BY ABOUT A THIRD FOR NEW AND
EARLY STAGE INVESTIGATORS AND
THIS IS A IMPORTANT STRATEGY
FOR SIMPLY NOT INCREASING
FUNDING FOR VERY ABLE AND
ESTABLISHED RESEARCHERS
BROUGHT TO THE FIELD AND WILL
NOW WE HAVE A NEW CATEGORY
CALLED NEW TO THE FILED AND
THOSE ARE INVESTIGATORS WHO
NEVER HAVE APPLIED FOR
RESEARCH AT NIH AND A FIFTH
WHO HAVE NEVER APPLIED FOR SO
THIS CONTINUES TO BE A HEALTHY
WAY FOR RECRUITING FOR THE
MOST DIVERSE AND AGING
POPULATIONS.
NEXT, YOU HAVE HEARD A LITTLE
BIT ABOUT THE REAL WORLD DATA
INITIATIVE.
YOU CAN SEE HERE IT IS A VERY
SUBSTANTIAL AND AMBITIOUS
ENTERPRISE DESIGNED TO LOOK AT
REAL WORLD DATA OF MULTIPLE
ORIGINS, TO LOOK AT THE
PHYSICAL SIFT AND
HARMONIZATION FOR A MULTITUDE
OF PURPOSES BUT YOU CAN SEE ON
THE LEFT THE KIND OF DATA WE
HAVE IN MIND, HEALTH RECORDS,
PHARMACY CHANGE, EVENTUALLY
MONITORING OF SOCIAL
DETERMINANTS OF HEALTH,
SENSORS, ALL TO COMPILE AN
INTEGRATED DATABASE WHICH IS
TARGETED TO FUND 80 PERCENT
COVERAGE WITHIN NARD AND THE
AVERAGE POPULATION.
THE PURPOSES NOTED, SCREENING,
RECRUITMENT, AS A MEANS OF
RECRUITING PEOPLE INTO
STUDIES, TRIALS, REPURPOSING,
LOOKING AT PEOPLE AT AN
OBSERVATIONAL LEVEL IN TERMS
OF FUNCTION, DEMENTIA
PROGRESSION FOR DRUG EXPOSURES
THAT CAN LEAD TO TRIALS.
LONG-TERM FOLLOW UP FOR
INDIVIDUALS WHO MAY BE UNDER
TREATMENT THAT ORIGINATED IN
CLINICAL TRIALS, HAPPEN TO
SAY -- WE'RE ALL VERY EXCITED
ABOUT THE FACT WE'RE NOW
SEEING ALZHEIMER'S TREATMENTS
WHICH ARE REFLECTING OUTCOMES
AND NOT YET TO THE POINT WE
WOULD LIKE THEM TO BE BUT
CERTAINLY PROMISING.
NOW IT IS CRITICAL FOR THE
PRESENT IN ALL THESE STUDIES
TO PUT CLINICAL TRIALS INTO
COMMON AND GENERAL USE.
WE FEEL REAL OBLIGATION TO
TRACK HOW THEY ARE PERFORMING
IN DIVERSE POPULATIONS THAT
CAN'T BE INCORPORATED ACTIVELY
BECAUSE IT IS A TRIAL AND AS
WELL AS ANY OTHER TRIAL THAT
MIGHT BE CONDUCTED WITH THESE
TRIALS.
TO APPLICATIONS BY JULY, THEN
PEER REVIEW AND IF THERE ARE
SUFFICIENT MERITORIOUS
APPLICATIONS TO FUND ONE, WE
WILL FUND IT IN FY24.
THE VIEW HERE WILL BE
PARTICULARLY CHALLENGING, THE
DEMAND IN TERMS OF CLINICAL
DATA MANAGEMENT, ETHICS, ALL
OF THESE INCORPORATED INTO A
PEER REVIEW WHO ARE NOT IN
CONFLICT WITH THE APPLICATION
AND THOSE LIKELY TO BE A VERY
LARGE CONSORTIA NOT DEPICTED
BEFORE.
AND TO ILLUSTRATE SOME OF
THOSE POINTS I MENTIONED IN
VOTED FORM.
NEXT.
A BIT OF A STRUCTURE, COMPLEX
COOPERATIVE AGREEMENT WHICH
MEANS NIA STAFF WILL BE
PLAYING AN IMPORTANT ROLE IN
WORKING WITH THE AWARDEE.
THERE ARE CONVENTIONAL
ADMINISTRATIVE CORES HERE BUT
YOU WILL NOTICE INCUBATIVE
TRIALS TO LOOK AT FEASIBILITY.
STAKEHOLDER PRIVACY AND ETHICS
CORE, WE MENTIONED IS AN
IMPORTANT ONE AND UNIQUELY
EMPHASIZE THE RNA THAT WENT
OUT AND INTEND TO FOLLOW UP IS
THE USE OF MILESTONES AND
STRICT ATTENTION TO THEM.
AND WE HAVE BEEN CAREFUL TO
OUR WORKING WITH NIH
AUTHORITIES TO MAKE SURE THAT
WE HAD IN THE RSA AND
THEREFORE IN TERMS AND
CONDITIONS OUR ABILITY TO
MONITOR IN THE FIRST MONTH HOW
PERFORMANCE IS OCCURRING AND
MAKE CHANGES TO ALTER THE ASK
SCIENCE, TO TERMINATE WORST
KATE FAILURES DECLARED, WHAT
WE HOPE TO MOST AVOID BUT BY
HAVING CLOSE SUPERVISION AND
ADVISORY GROUPS, LOOKING AT
THIS AS IT EVOLVES AND ONE
WHICH IS A VERY EXCITING
POTENTIAL BUT ONE WE DON'T
TAKE LIGHTLY.
NEXT, PLEASE.
YOU HEARD A LITTLE ABOUT THIS
ONE YESTERDAY, THE NIA HEALTHY
AGING STARTUP CHALLENGE AND IT
REVOLVES AROUND OUR SMALL
BUSINESS ENTERPRISE AND
REALIZATION THAT ONLY SMALL
FRACTIONS OF THOSE WHO RECEIVE
PH.D., MD DOCTORAL DEGREES IN
BEHAVIORAL OF SOCIAL AND
BIOLOGICAL SCIENCES END UP IN
CLASSIC, IF YOU WILL, ACADEMIC
CAREERS SO TO PREPARE FOR
INDIVIDUALS WHO MIGHT CHOOSE
TO MOVE INTO MORE
ENTREPRENEURIAL AREAS AND TO
IMPORTANTLY REINFORCE THE
ENTREPRENEURIAL SEGMENTS WITH
THE KIND OF TALENT THAT IS
NEEDED TO ESTABLISH THIS
PROGRAM WITH APPLICATIONS.
FIRST YEAR FISCAL 22, OVER 200
APPLICATIONS PEOPLE ARE
MAKING.
WE STARTED TO DISCUSS
YESTERDAY THEIR INTENT TO
DEMONSTRATE THE WAY THEY
PROPOSE THE SCIENCE THEY ARE
DOING AND HOW IT IS
COMMERCIALLY TRANSLATABLE.
THEY HAVE LONG-TERM
ESTABLISHED RELATIONSHIPS WITH
MENTORS IN THE FIELD, EXPERTS
IN ENTREPRENEURIAL RESEARCH.
AS A RESULT OF THEIR FIRST
EFFORTS THERE IS A NARROWING
DOWN TO A SET OF FINALISTS.
IN THE PAST YEAR, WE TOOK
THOSE 20 FINALISTS WHO
RECEIVED MORE INTENSIVE BOOT
CAMP TRAINING FOR A FINAL
AWARD OF $50,000 CASH TO BEGIN
THE RESEARCH THAT PUTS THEM ON
THE ROAD TOWARDS
ENTREPRENEURIAL WORK.
YOU CAN SEE THE DIVERSITY
ACHIEVED IN THE AWARDEES HERE
AND THE TOPICS.
SO QUITE GRATIFYING AND CREDIT
TO STAFF AT NIA WHO HELPED PUT
TOGETHER THIS VERY INNOVATIVE
PROGRAM.
NEXT, PLEASE.
LET'S SEE, RESEARCH SUM MITTS
HELD ON AN A BASIS.
THIS YEAR, 2023 MARCH,
INCLUDED THE CARE SERVICE AND
SUPPORT FOR PERSONS LIVING
WITH DEMENTIA AND THEIR CARE
PARTNERS, I HOPE THIS HAS BEEN
ARCHIVED AND THE RECORDING IS
SHOWN HERE THAT OPTIMIZE THE
RESEARCH AND CONTINUED
INNOVATION.
THIS IS THE FOURTH HELD LAST
MONTH IN APRIL, THE INSTANCE
YOU SEE HERE IN EIGHT
BIOLOGICAL SESSIONS, WANT TO
LOOK AT DETERMINANTS OF HEALTH
AND HEALTH DISPARITIES, A NEW
ENTITY FOCUS IN THE
GERI-SCIENCE AREA AS WELL AS
HIGH LOW DYSFUNCTION
MULTIDEFICITS, MEASURING
HEALTH, MODELING OF THE DATA
WE HAVE AROUND HEALTHY, AGING
AND LONGEVITY BIOMARKERS FOR
GERISCIENCE AND THE NATURE OF
THE TRIALS.
SO I HOPE MANY PEOPLE ARE ABLE
TO ATTEND AND THIS HAS NOT
BEEN ARCHIVED YET.
[INAUDIBLE]
>>VERY GOOD.
THANK YOU, NEXT.
WITH OUR CONSTANT EFFORTS TO
DISSEMINATE PROGRESS AS A
RESULT OF THE NIH RESEARCH, AN
EXAMPLE OF PRESS RELEASES AND
HIGHLIGHTS IN A WAY WE WORK
WITH STAKEHOLDERS AS WELL AS
PARTICIPATING IN CONGRESSIONAL
BRIEFINGS AND HEARINGS.
NEXT, PLEASE.
OKAY, NEXT, SOME UPDATES.
AMONG THE COMMON FUND
INITIATIVES THAT HAVE BEEN OF
GREATEST RELEVANCE TO OUR NIA
MISSION THAT MANY HAVE IS THE
CELLULAR SIN SYNAPTIC NETWORK.
MANY OF YOU MAY BE AWARE THE
COMMON FUND WITHIN THE OFFICE
OF THE DIRECTOR OF NIH AND
AMONG ITS ACTIVITIES LOOKS
EACH YEAR AT INITIATIVES THAT
ARE OF HIGH IMPORTANT AND THAT
SPAN THE INTEREST OF MOST OF
OF THE CENTERS AND ONE OF
THESE IS THE CELLULAR NETWORK
THAT BEGAN AND CONTINUES WITH
PRIMARY LEADERSHIP FROM NIA
AND NCI.
WE'RE AT THE STAGE NOW WHERE
WE ARE BEGINNING TO SEE SOME
CONCRETE PROGRESS IN RESEARCH,
A MEETING OF INVESTIGATORS
GENERALLY THIS YEAR WAS REALLY
A VERY EXCITING OPPORTUNITY.
SOME OF YOU WERE THERE.
AND THIS WILL PROVIDE I THINK
A SYSTEMIC INFRASTRUCTURE THAT
WILL THEN TAKE OFF THROUGH THE
APPLICATIONS.
HUMAN AND MOUTH IN WHICH THE
STIMULATIONS AND A VARIETY OF
SYSTEMS HAPPEN THAT WILL BE
THE BASELINE OF DATA FOR A
GREAT DEAL OF RESEARCH TO
COME.
NEXT SLIDE.
THE COUNCIL WITH
INFRASTRUCTURE RACISM,
PARTICULARLY THROUGH RUBIN
KNIGHT WHAT HAS BEEN A VERY
ACTIVE LEADER IN THIS AREA AND
I STRESS AGAIN THE NIH
COMMITMENT TO IT, YOU CAN SEE
SOME OF THE PEOPLE INVOLVED IN
LEADERSHIP THERE, FRANK,
PATRICIA.
AND IN ADDITION TO OUR
COMMITMENT INCIDENT TAOUPBLGS
ALLY TO THESE PRINCIPLES, OUR
PREVIOUS DIRECTOR MARIE
BERNARD IS PLAYING A ROLE AND
WILL IT IS WITH GREAT
EXCITEMENT WE WERE ABLE TO
RECRUIT AMY KELLY FOR MULTIPLE
REASONS BUT AMONG OTHERS, FOR
HER ROLE AND RESPONSIBILITIES
IN LEADING NIA EFFORTS IN THIS
AREA.
NEXT, PLEASE.
THE INAUGURAL REPORT IS GOING
TO BE DESCRIBED AS A SELECTIVE
ACHIEVEMENT IN 21-22, THE
YEARS IT HAS BEEN IN EXISTENCE
AND HERE IS A LINK ON THE
SLIDE AS WELL.
NEXT SLIDE.
NIH STRATEGY AND PLAN
PUBLISHED AND THIS IS A
SIGNIFICANT PLAN FROM YEARS
23-27.
NEXT, AND WE WILL TURN NOW TO
A DELIGHTFUL ASPECT OF WHAT WE
DO FOR NIH STAFF, UPDATES IN
TERMS OF NEW RECRUITMENT,
THERE HAVE BEEN A GREAT NUMBER
AND I JUST TO WANT SHARE THE
INFORMATION YOU ARE SEEING AT
THE NIH LEVEL IN TERMS OF WHAT
IS NEW AND THE PRESIDENT WILL
BE NOMINATING MONICA FOR THE
NIH DIRECTOR POSITION.
SHE HAS BEEN THE NCI DIRECTOR
SINCE OCTOBER, THE FIRST
WOMAN, FEMALE DIRECTOR OF NCI
WOULD IF BE THE SECOND NIH
DIRECTOR.
JUST TO REMIND YOU THE NIH
DIRECTOR POSITION IN ADDITION
TO DIRECTIONS, NOMINATIONS BY
THE PRESIDENT REQUIRES SENATE
APPROVAL FOR THIS PROCESS TO
CONTINUE WE HOPE WITHOUT DELAY
AND LOOK FORWARD TO HAVING NIA
LEADERSHIP AS WELL AND
RECRUITING FOR DEPUTY DIRECTOR
AS WELL.
SO LET ME TURN IT OVER TO THE
LEADERSHIP AND ONCE WE'RE
THROUGH HERE, I WILL BE HAPPY
TO UNDERTAKEN ANY QUESTIONS
YOU MAY HAVE ON ANY GENERAL
TOPIC SO WE START WITH THE
NAB.
>>WELCOME.
RON COHINSKI, DIRECTOR OF
INSTITUTIONAL AGING BIOLOGY
AND PLEASURE TO ANNOUNCE THREE
NEW STAFF MEMBERS SHOWN HERE
WHO COME TO US THROUGH NIAA
AND ANDRES HAS THE PORTFOLIO
APPROACHING HOMEOSTASIS AND
CALLED THE PORTFOLIO OF
RANGING ACTIVITY ON CELLULAR
NETWORK BEFORE HE JOINED THE
NATIONAL INUSE IT ON AGING AND
JUST AS BACKGROUND, PROTEIN
BIOLOGY WOULD BE THE SIMPLEST
WAY TO PUT IT.
AND Dr. SARANG IS JOINING US
FROM SEVERAL INSTITUTES ACROSS
HERE CAREER, II GM S, NIAMS,
NHLBI, HER FIRST EXPERIENCE
ACROSS NIH HAS ALREADY PROVEN
INVALUABLE TO AGING BIOLOGY
AND NIA INVOLVED.
NEXT SLIDE, PLEASE.
PROGRAM DIRECTOR FOR HIV AND
AGING RESEARCH, THIS IS A
TRANSNIA POSITION HOUSED IN
THE DIVISION OF AGING BIOLOGY.
AND SHE HAS A LONG HISTORY OF
WORKING IN THE AREAS OF HIV
RESEARCH.
WELCOME TO ALL THREE NEW STAFF
MEMBERS.
THANK YOU.
>>NEXT SLIDE, PLEASE.
HI, I AM --
[INDISCERNIBLE]
AND I WOULD LIKE TO EXTEND A
WELCOME TO OUR NEW STAFF.
FIRST, A VANA JOINS AS A
PROGRAM ANALYST -- [INAUDIBLE]
SHE JOINS US FROM THE NIH
PLATFORM WITH A DEGREE --
[INDISCERNIBLE]
NEXT UP, Dr. HOOKER JOINING
AS A PROGRAM OFFICER TO
OVERSEE OUR PORTFOLIO ON
SPECIAL BIOLOGY AND --
[INDISCERNIBLE]
SHE JOINS US UNC CHAPEL HILL
WHERE SHE COMPLETED HER
POST-DOC TRAINING IN
PSYCHOLOGY AND SOCIAL
BEHAVIOR.
NEXT SLIDE, PLEASE.
AND NEXT I WOULD INTRODUCE
Dr --
[INDISCERNIBLE]
, THANK YOU.
JOINS US AS DEPUTY DIRECTOR OF
THE OFFICE OF DATA RESOURCES
AND SO FAR COORDINATING A
VARIETY OF DATA RELATED TO
RESOURCES.
HAS A DOCTORATE IN HEALTH
SCIENCES AND A MASTER IN
HEALTH SCIENCES --
[INDISCERNIBLE]
AND ALSO WITH US IN THE ROOM,
EVERYONE SAY HI TO COSIA,
JOINS US IN HSR TO MANAGE OUR
FIELD EXPERIMENTING PROCESS
RELATED TO MACRO SOCIAL
FACTORS AND DRIVERS OF SOCIAL
HEALTH THAT ARE THE LIFE
FORCE.
EXPERTISE IN MICRO BIOLOGY AND
JOINS US FROM HHS, OFFICE OF
FAMILIES AND EVALUATION.
AND NEXT SLIDE PLEASE, LAST
BUT NOT LEAST, KATHY JOINS US
AS STAFF ASSISTANT PRIMARILY
SUPPORTING CRITICAL FUNCTIONS
FOR HSR, JOINS US FROM AN
INSURANCE COMPANY WHERE SHE
WAS AN UNDER WRITING
SPECIALIST, SERVES AS SUMMER
ADMINISTRATIVE INTERN AND HAS
A BACHELOR OF ARTS.
[INAUDIBLE]
>>ALL RIGHT, THANK YOU, GOOD
MORNING, EVERYBODY, I AM
ELLIOT, DIRECTOR OF THE
DIVISION OF NEUROSCIENCE AND I
WILL USE MY PLACE HERE TO
INTRODUCE THE NEW RECRUITS TO
THE POSITION OF NEUROSCIENCE
STARTING WITH CASSIE GREEN,
JOINING US AS A PROGRAM
ANALYST, WORKING ON THE
DIRECTOR'S OFFICE TOGETHER
WITH ME AND JENNY LARKIN AND
SHE WILL BE PROVIDING
PROGRAMATIC SUPPORT INCLUDING
FAILURE ANALYSIS AND
MANAGEMENT OF A NUMBER OF
FUNDING OPPORTUNITIES.
SHE COMES FROM NHLBI AND HAS
ALREADY DONE REALLY TREMENDOUS
AMOUNT OF WORK.
NEXT WE HAVE MAYA WHO JOINS US
FROM NIAAD AND IS AN
IMMUNOLOGIST WITH TRAINING
FROM NYU AND YALE UNIVERSITY
WITH TREMENDOUS EXPERIENCE ON
VIROLOGY, TUMOR BIOLOGY AND SO
ON AND SHE IS JOINING THE
PROGRAM DIRECTOR IN THE
NEUROBIOLOGY OF AGING AND
NEUROREDEGENERATION BRANCH
WHERE SHE WILL BE OVERSEEING
ALL THE PROGRAMS ON
IMMUNOLOGY, VIROLOGY INCLUDING
HIV, COVID AND SO ON.
AND NEXT WE HAVE KANG JOINING
US FROM THE ALL OF US PROGRAM
FROM NIHOD AND KANG IS
ACTUALLY GOING TO BE OUR NEW
DOC DIRECTOR FOR NIAS AND ALSO
HELPING COORDINATING OWL THE
DATA SHARING AND ALL THE OTHER
PROCESSES RELATED TO GENE THOM
MIX DATA.
SHE HAS DEGREES -- GENOMICS
DATA, DEGREES FROM HOWARD
UNIVERSITY.
NEXT SLIDE, PLEASE.
AND MOST RECENTLY WE HAVE
JOSLYN RIVER JOINING US, PART
OF THE BEHAVIORAL AUTISTIC
SCIENCE BRANCH WHERE SHE HAS
BEEN PROVIDING SUPPORT TO THE
PROGRAM DIRECTOR ACROSS
MULTIPLE BRANCHES IN DATA
MANAGEMENT, SHARING,
EVALUATION, CLINICAL TRIAL
MONITORING AND SO ON.
JOINS US FROM UPENN AND PRIOR
TO THAT, JUSTIN HAS DEGREES
FROM IOWA UNIVERSITY AND
PRINCE TON UNIVERSITY.
AND LAST BUT NOT LEAST, WE
HAVE BROOK TO JOINS US
ACTUALLY FROM THE POSTAL
SERVICE AND SHE IS PROVIDING
SUPPORT ON TRAVEL COORDINATION
AND A NUMBER IT HAVE OTHER
INTERNAL OFFICES AND DIVISION
FUNCTIONS RELATED TO OFFICE
ADMINISTRATION AND SHE IS IN
THE OFFICE OF THE DIRECTOR.
SO THANK YOU VERY MUCH AND
WELCOME TO ALL OF THEM.
[APPLAUSE]
>>ALL RIGHT, NEXT UP IS THE
DIVISION OF EXTRA MURAL
ACTIVITY WITH KEN AS DIRECTOR
AND WE HAVE BEEN VERY
FORTUNATE THIS ROUND TO HIRE
SOME REALLY OUTSTANDING NEW
STAFF SO I WOULD LIKE YOU ALL
TO WELCOME THEM.
FIRST OFF IS TERESA LING,
HEALTH SCIENCE ADMINISTRATOR
IN THE OFFICE OF THE DIRECTOR
AND SHE JOINS US FROM THE BDIT
IN SUPPORT OF THE WALTER REED
INSTITUTE OF RESEARCH AND WILL
NOW SERVE AS ONE OF OUR
REFERRAL LIAISONS FOR OUR
INSTITUTE.
I THINK TERESA YOU ARE HERE?
YOU WANT TO GIVE A WAIVE?
THANK YOU.
NEXT WE HAVE SHERYL IN THE
OFFICE OF THE CHIEF OF
CLINICAL RESEARCH, THIS IS A
NEW POSITION CREATED TO
SUPPORT OUR CLINICAL RESEARCH
THROUGHOUT THE INSTITUTE.
WE WELCOME SHARON SMITH AND
SHE IS GOING TO OVERSEE AND
COORDINATE THE DEVELOPMENT AND
IMPLEMENTATION TO ENHANCE
DIVERSITY, EQUITY AND
INCLUSION FOR NIA FUNDED
CLINICAL TRIALS AND ALSO GOING
TO BE THE MAJOR CONTACT FOR
OUR CLINICAL RESEARCH
OPERATIONS MANAGEMENT SYSTEM
THAT MANAGES ALL OF OUR
CLINICAL TRIALS HERE AT THE
INSTITUTE AND SHE'S JOINING US
FROM THE MENTAL HEALTH
INSTITUTE.
NEXT SLIDE.
WE HAVE OUR SCIENTIFIC REVIEW
BRANCH WAS ABLE TO HIRE
SEVERAL NEW SCIENTIFIC REVIEW
OFFICERS.
FIRST OFF, WE HAVE CAITLYN
HARDELL.
SHE IS JOINING US FROM THE
CANCER INSTITUTE AND WILL BE
ONE OF OUR NEW SCIENTIFIC
REVIEW OFFICERS IN THE
INFORMATION RESOURCES AND
POLICY SECTION.
WE HAVE MARIELLE DIAZ JOINING
US FROM GEORGE WASHINGTON
UNIVERSITY.
SHE IS GOING TO IT BE A
SCIENTIFIC REVIEW OFFICER IN
THE SPECIAL REVIEW INFORMATION
RESOURCES AND POLICY SECTION
ALSO.
NEXT SLIDE.
WE HAVE Dr. NAZAR ACONDA AND
HE WILL BE A NEW SRO IN THE
CLINICAL SCIENCES SECTION IN
OUR SCIENTIFIC REVIEW BRANCH
AND HE JOINS US FROM THE
UNIVERSITY OF CENTRAL FLORIDA.
AND WE HAVE CHRISTINA FOWLES
AND SHE IS A PATHWAY STUDENT
AND WILL BE PART OF OUR
SUPPORT STAFF FOR THE
SCIENTIFIC REVIEW BRANCH.
NEXT SLIDE.
WE HAVE SEVERAL NEW HIRES IN
OUR GRANTS AND CONTRACTS
MANAGEMENT BRANCH.
FIRST OFF WE HAVE BRIA HARRIS,
SHE WILL BE A NEW GRANTS
MANAGEMENT SPECIALIST JOINING
US FROM THE OFFICE OF PLANNING
AND BUDGET FROM GEORGIA.
AND TELLEHA HOWARD, NEW GRANTS
MANAGEMENT SPECIALIST AND
JOINING US FROM THE CENTER OF
DISEASE CONTROL AND
PREVENTION.
NEXT SLIDE.
YOLANDA JONES, ANOTHER GRANTS
MANAGEMENT SPECIALIST JOINING
US FROM THE STATE OF
CALIFORNIA UNIFIED SCHOOL
DISTRICT AND JESSICA JOSEPH,
ANOTHER GRANTS MANAGEMENT
SPECIALIST WHO JOINS US FROM
THE TEAM OF INFECTIOUS
DISEASES.
NEXT SLIDE.
WE HAVE TRACY McGRAW, GRANTS
MANAGEMENT SPECIALIST JOINING
US FROM THE CANCER INSTITUTE
AND CAROLINE MIKLOS JOINING US
FROM JOHNS HOPKINS UNIVERSITY.
NEXT WE HAVE CAROLYN PHILIPPS
WHO WILL BE STAFF ASSISTANT IN
THE GRANTS MANAGEMENT BRANCH
ASSISTING TRACY LAFFERTY, OUR
CHIEF GM O.
KRISTINA SMITH ANOTHER GRANTS
MANAGEMENT SPECIALIST JOINING
US FROM A NONPROFIT
ORGANIZATION AS PROGRAM
COORDINATOR AND TIFFANY
SWANSON FINALLY JOINS US FROM
MORGUE DAN STATE UNIVERSITY.
SO YOU CAN SEE WE HIRED A
LARGE COHORT OF GRANTS
MANAGEMENT SPECIALISTS TO
HANDLE THE HUGE LOAD OF GRANTS
ISSUES THAT WE HAVE FOR THE
INSTITUTE THAT IS CREATED BY
THE INCREASE IN BUDGET SO
WE'RE DOING SO MANY MORE
ACTIONSS.
THIS WAS A NEW CONCEPT THAT WE
HIRED THE ENTIRE COHORT AS
GRANTS MANAGEMENT SPECIALISTS
TO KEEP THE PIPELINE GOING AT
THE INSTITUTE.
NEXT SLIDE, PLEASE?
>>GOOD MORNING I AM KAREN AND
I AM HERE ON BEHALF OF PATRICK
SHERIDAN, EXECUTIVE OFFICER
WHO ISN'T HERE THIS MORNING.
HERE TO INTRODUCE YOU TO THE
OFFICE OF ADMINISTRATIVE
MANAGEMENT NEW STAFF IN THE
WORKFORCE ADMINISTRATOR
BRANCH.
WE HAVE ERIN GOTZENS, NEW
ADMINISTRATIVE OFFICER, JOINS
US FROM REAL ESTATE TITLE
SERVICES AND MARISA MULLEN,
JOINS US FROM NIAID.
NEXT SLIDE.
IN THE TECHNOLOGY BRANCH, WE
HAVE KRISTEN JOINING US AS
PROGRESS SPECIALIST AND WE
ALSO HAVE WENDY SCHNEIDER,
JOINING ALWAYS FROM FAMILY
SERVICES OF RHODE ISLAND AND
OMAR SET TELLS, NEW IT
SPECIALIST AND SECURITY
OFFICER AT THE BALTIMORE BIC
BUILDING AND JOINS US FROM
'TIS DETAIL-- TISTA.
>>SO FROM THE OFFICE OF
DIRECTOR, BESIDES MYSELF BEING
RELATIVELY NEW, WE HAVE
ANOTHER NEW PHYSICIANS,
MICHELLE NEWELL, STAFF
ASSISTANT SERVING THE DEPUTY
DIRECTOR AND PRIOR TO COMING
TO NIA WAS AN OFFICE MANAGER
AT A LOCAL MEDICAL PRACTICE
AND JOINS IS A GRADUATE OF
CLEMSON UNIVERSITY WITH A
BACKGROUND IN BIOLOGY.
>>HELLO, I AM COURTNEY WALL,
DEPUTY DIRECTOR FROM THE
OFFICE OF LEGISLATION, POLICY
AND INTERNATIONAL ACTIVITIES
HERE TO INTRODUCE SHANTE
ALERTE WHO JOINED OUR STAFF
BACK IN FEBRUARY.
SHE IS ALSO EFFECTIVELY
MANAGING THE ADMINISTRATIVE
AND OPERATIONAL FUNCTIONS OF
OUR OFFICE AND HANDLING
SEVERAL HIGH-LEVEL PROJECTS
FOR US AND JOINS US FROM NIH
ALL OF US RESEARCH PROGRAM AND
CAN'T EMPHASIZE ENOUGH HOW
CRITICAL HER ROLE HAS BEEN
WITH THE NEEDING QUICK
TURNAROUND ON SOME PROJECTS.
THANKS.
>>CINDY McCON NELL,
DIRECTOR OF THE OFFICE OF
COMMUNICATIONS AND PUBLIC
LIAISON.
WE WELCOMED RECENTLY FEDORA
BRAVERMAN, SHE IS BI LINGUAL
AND WILL BE SERVING AS HEALTH
COMMUNICATIONS SPECIALIST TO
HELP WITH THE SPANISH LANGUAGE
HEALTH COMMUNICATIONS WE OFFER
TO OUR AUDIENCE.
FEDORA WAS PREVIOUSLY AT THE
NATIONAL CANCER INSTITUTE.
>>HI, SO NIA, THE ISC IS
QUITE ACTIVE AND HAVE GROWING
AND THESE ARE THE THREE NEW
ADMINISTRATIVE OFFICERS,
JENNIFER BETTER REWHO JOINS US
FROM THE ARMY U.S. CORPS OF
ENGINEERS, WILLIAM HOFF
JOINING US FROM THE DEPARTMENT
OF JUSTICE AND JESSICA
WHITAKER, JOINING US FROM THE
NIGMS.
NEXT SLIDE.
SO WE HAVE TWO NEW HIRINGS,
KELLI VAN ZEE, JOINS US FROM
THE NATIONAL PARK SERVICE,
VERONICA RYAN FROM NINDS AND
LAUREL SCREVEN, SCIENTIFIC
PROJECT MANAGER AND JOINS US
FROM KELLY GOVERNMENT
SOLUTIONS.
NEXT.
WE ARE NEW SERVICES TO HANDLE
THE PROJECTS IN THE COMMUNITY
AND JADE TALMADGE JOINS US
FROM WALT PER READ NATIONAL
MILITARY MEDICAL CENTER AND
DIMITRIOS TSITSIPATIS,
RESEARCH FELLOW, EXPERT IN RNA
SEQUENCING PROJECTS.
NEXT SLIDE.
WE HAVE CAIO MAZUCANTI,
RESEARCH FELLOW JOINING US
FROM THE UNIVERSITY OF SAO
PAULO.
WE HAVE LESLIE VUNCANNON,
EDITORIAL ASSISTANT IN
TRANSLATIONAL GERONTOLOGY
BRANCH AND WILL BE HELPING US
WITH ALL THE ADVANCED
AUTOMATION TECHNOLOGY GROWING
IN NIH.
NEXT SLIDE.
SO WE HAVE SYED ABBAS BUKHARI
AS STAFF SCIENTIST WORKING ON
GENETIC DATA AND FLOW
CYTOMETRY DATA.
FATIMA BRAIKIA WILL BE
RESEARCH FELLOW WORKING
CLOSELY WORKING WITH
LABORATORY OF MOLECULAR
BIOLOGY AND IMMUNOLOGY.
NEXT SLIDE.
AND THEN TWO MORE JOINING THE
INSTITUTE, MICHLYO IBA,
JOINING US FROM KELLY
GOVERNMENT SOLUTIONS AND VERY
MUCH INTERESTED IN
INFLAMMATION ESPECIALLY
PARKINSON'S DISEASE AND MINKYO
SONG, TENURE TRACK
INVESTIGATOR JOINING US FROM
NCI AND I THINK THAT IS IT.
>>THANK YOU VERY MUCH AND
PLEASE SEND A WARM WELCOME TO
OUR NEW STAFF HERE AT NIA.
NOW WE HAVE TIME FOR QUESTIONS
FOR Dr. HODES REGARDING HIS
PRESENTATION EARLIER.
ANY QUESTIONS?
>>I WILL COVER ANYTHING YOU
WOULD LIKE TO BRING UP.
>>YES, NIH HAS A LOT GOING ON
IN ALZHEIMER'S'S RELATE
DISORDERS AND THE INTRAMURAL
BRANCH, YOU HEARD ABOUT KARS
REALLY GETTING OFF THE GROUND,
A O C PROGRAMS AND A NUMBER OF
OTHER PROGRAMS IN INDIVIDUAL
STATIONS.
IS THERE A COORDINATED METHOD
OF MAKING SURE THAT THERE IS
NOT DUPLICATION AND THAT
EVERYTHING IS COVERED?
YOU KNOW, ACROSS ALL THESE
INITIATIVES?
>>YEAH, IT IS A GREAT
QUESTION.
SO THERE ARE A NUMBER OF
PLACES WHERE OUR EFFORTS IN
ALZHEIMER'S COLE LESS AND
COALESCE AND ONE OF THEM IS
THE STRATEGIC BY PASS PROJECT.
FOR THOSE NOT FAMILIAR, THE
NATIONAL ALZHEIMER'S PROJECT
ACT, THERE IS A REQUIREMENT
FOR NIH, A NIH DIRECTOR EACH
YEAR TO SUBMIT TO CONGRESS
WHAT IS CALLED A PROFESSIONAL
JUDGMENT BUDGET AND ENUMERATE
THE FUNDS NECESSARY ABOVE
CURRENT FUNDING LEVELS IN
ORDER TO OPT HALLE PURSUE THE
ALZHEIMER'-- OPTIMALLY PURSUE
ALZHEIMER'S.
THIS EACH YEAR GENERATES A
SERIES OF MILESTONES THAT ARE
THE OUTCOME OF IDENTIFIED GAPS
AND OPPORTUNITIES FROM SUCH
EXERCISES AND INPUT AT THE
SUMMIT AND THE SUMMIT AS YOU
SEE, THERE ARE THREE FLAVORS
OF SUMMITS, THE ALZHEIMER'S
SUMMIT, THE RESOURCES SUMMIT
AND THE THIRD ONE THAT
OCCURRED THIS YEAR AND AFTER
EACH, THERE IS A SECTION OF
RECOMMENDED OPPORTUNITIES
TRANSLATED INTO MILESTONES.
MILESTONES NEEDED TO ACHIEVE
EACH OF THOSE GOALS.
THE MILESTONES THEN ARE USED
AS A GUIDE FOR OUR GENERATION
OF INITIATIVES AS PART OF OUR
INTEGRATED PLANNING PROCESS AT
THE INSTITUTE -- I AM GIVING
YOU THE FORMAL ASPECT BUT
RIGHT NOW WE ARE BUILDING
TOWARDS A -- NEXT MONTH OUR A
PLANNING RETREAT IN WHICH THE
WHOLE INSTITUTE GETS TOGETHER
AND PROBABLY IN THIS ROOM FOR
THREE DAYS AND LOOKS AT A
SERIES OF INITIATIVES FOR
TARGETED RESEARCH AND THESE
INCLUDE MANY THAT ARE NIA AAD,
SOME ARE NOT BUT AGAIN WITH
PLANNING COLLABORATION BEFORE
HAND AND FURTHER DISCUSSION AT
THE TIME OF THE RETREAT SO THE
BUDGET WITH FORWARD LOOKING
IDENTIFICATION OF PRIORITY
AREAS AND INTERNAL STRATEGIC
PLANNING PROCESS WHICH
INCLUDES ACTUALLY SET ASIDE
MISSIONS WHICH YOU KNOW WELL
WITH THE CONSEQUENCES BEFORE
WE GO FURTHER AND OVERALL
COMPREHENSIVE POINTS IN WHICH
WE EMPHASIZE OUR PLANNING
EFFORTS.
[INAUDIBLE]
[ OFF MIC ]
>>YOU KNOW WE LOOK AT THE
NUMBER OF PLANNING INITIATIVES
FROM THE STUDIES AND SUMMITS
AND THE OTHER ALZHEIMER'S
ONES, BUT SITTING DOWN AND
SAYING OH, I WILL TAKE THIS
ONE, I WILL TAKE THAT ONE, AND
YOU KNOW MAKING SURE THAT
EVERYTHING IS COVERED WITHOUT
DUPLICATION.
I THINK THEY DO OCCUR AROUND
THE BY PASS BUDGET STRATEGY.
SO EACH YEAR FOLLOWING THE
RETREAT, THAT IS SORT OF THE
TRIGGER WITH NEW OPPORTUNITIES
WE HAVE IDENTIFIED, WE MAKE
THE LINKS AVAILABLE TO A
MILESTONE DOCUMENT WHICH IS
INTENDED TO BE QUITE
COMPREHENSIVE, OVER 100
MILESTONES IN A VARIETY OF
AREAS THAT RANGE FROM THE MOST
MOLECULAR IDENTIFICATION OF
CLINICAL TRIALS HERE, ALL OF
THIS.
AND THEN THAT EXERCISE EACH
YEAR IS ONE AT WHICH THERE IS
A LOOK FOR, BY DEFINITION, GAS
OPPORTUNITIES AND AVOID
DUPLICATION TO BE SURE BUT I
THINK IN A VERY HEALTHY WAY,
ALWAYS OUR RESEARCH IS DRIVEN
BY OUR TARGET INITIATIVES THAT
ARE SET ASIDE AND THEN THE
RESEARCH AS THAT IS VERY
BALANCED SO WE WANT TO HAVE A
GUIDE BUT NOT MISS INITIATED
RESEARCH.
SO I THINK YOU ARE ASKING WHO
DECIDED WHAT IS COVERED OR
NOT, THAT FALLS IN OUR BY PASS
STRATEGY AND THEN OUR PLANNING
RETREAT WHERE ALL THE ISSUES
ARE THERE, HOPEFULLY WE ALL
WORK TOGETHER ON THIS --
[INDISCERNIBLE]
>>MOST OF THE INTRAMURAL
BRANCH AS WELL?
>>IN TERMS OF THE REPORTING
AND BY PASS BUDGET, YES THAT
IS GOING TO BE VERY IMPORTANT
BUT REMEMBER BECAUSE OF
THEVERY DIFFERENT RULES THAT
GUIDE THE INTRAMURAL AND
EXTRAMURAL PROGRAMS, THEY FOR
EXAMPLE DON'T BUDGET IN THE
SPECIFIC DETERMINATION OF
WHICH ARE THEY ALLOWING FOR
TARGETED FUNDING IN THE
EXTRAMURAL COMMUNITY.
THE SCIENTIFIC RETREAT IS
EXTREMELY IMPORTANT BUT THEY
HAVE THE LINE ITEM IN OUR
BUDGET WITH THEIR RESEARCH.
WHAT THEY ARE DOING IS VERY
MUCH COORDINATED WHAT HAPPENS
WITH A SEPARATION OF
INTRAMURAL AND EXTRAMURAL
DECISIONAL MECHANISMS.
>>AND MAYBE I COULD ADD
ACROSS INSTITUTES, ALSO.
THERE IS A LOT OF COORDINATED
EFFORT IN OUR PROGRAMS IN
OTHER INSTITUTES AND THEN
THERE IS VERY STRICT RECEIPT
AND REFERRAL GUIDELINES AND
THE OVERLAP BETWEEN INSTITUTES
THAT GUIDE WHERE PARTICULAR
AREAS OF SCIENCE ARE MOST
APPROPRIATELY, YOU KNOW, PUT
INTO THAT PARTICULAR
INSTITUTE, EVEN THOUGH LIKE
Dr. HODES MENTIONED, THE
PROGRAM FOR ALZHEIMER'S
DISEASE SUPPLEMENTS TO
NONALZHEIMER'S DISEASE GRANTS
THROUGHOUT I THINK 21 OTHER
INSTITUTES, ALL OF THAT MONEY
IS COMING FROM US TO THOSE AND
MOVING FURTHER ALONG THE FIELD
BUT THAT IS AN EXPANSION IN
THE FIELD ABOUT ALZHEIMER'S
DISEASE AND THEN THAT BECOMES
PART OF THE PORTFOLIOS IN
THOSE INTEREST TOOT ALSO BUT
IT IS VERY STRICT IN, YOU
KNOW, THAT AREA OF RESEARCH
DOES GO TO THAT INSTITUTE AND
THEN THEY MONITOR EACH OF
THOSE PORTFOLIOS ENSURING
THERE IS NOT OVERLAP BETWEEN
THE INSTITUTES.
>>AND AGAIN I WOULD EMPHASIZE
THE IMPORTANT COLLABORATION
ACROSS NIH, WHAT INSTITUTE MAY
HAVE A PRIMARY ROLE, THERE IS
A VERY ACTIVE AND PRODUCTIVE
COLLABORATION ACROSS THE
INSTITUTE THAT IS A COFUNDING
THAT IS EVIDENT IN MANY AREAS,
LONGITUDINAL STUDIES IMPORTANT
IN LEVERAGING FUNDING AT NIH
AND COLLABORATION IS A VERY
IMPORTANT PART OF WHAT WE ARE
DOING AS WELL.
>>I DON'T HAVE A QUESTION, I
HAVE A COMMENT.
EVERYBODY IS LIKE --
[INDISCERNIBLE]
THERE HAS BEEN A LOTT OF
DISCUSSION IF DIVERSITY AT NIH
AND VERY IMPORTANT AS WE CAN
SEE IN THIS ROOM.
I WOULD LIKE TO SUGGEST TO
MAYBE EXTEND IT A LITTLE BIT
TO INCLUDE COLLEGE LEVELS.
IN THE TRUE SENSE WE THINK OF
DIVERSITY --
[INDISCERNIBLE]
BUT IF YOU GIVE AN OPPORTUNITY
TO FIRST ENRICH COLLEGE
RESIDENTS, YOU ARE CREATING A
ROLE MODEL.
I KNOW THIS FOR A FACT BECAUSE
I HAVE WORKED IN IN A
COMMUNITY.
CURRENTLY I KNOW SO MANY OF
THEM THE IF FIRST YEAR, ONES I
MENTORED, THEY HAD NO ROLE
MODEL, NOBODY THAT WENT TO
SCHOOL, NOBODY THAT WENT TO
COLLEGE IN BIOMEDICAL FIELD.
THEY HAVE ROLE MODELS IN THEIR
COMMUNITIES, IN THEIR FAMILIES
AND --
[INDISCERNIBLE]
AND I THINK IT IS JUST A
THOUGHT BUT I HEAR A LOT OF
TALK ABOUT DIVERSITY, I NEVER
HEAR ABOUT SOMETHING LIKE THAT
THAT PROBABLY SHOULD BE A PART
OF THAT CONVERSATION.
THANK YOU.
>>YOU EXPECT SOME SWAEPBGS
OVERLAP BUT NOT IDENTITY IN
THE GENERAL CRITERIA AROUND
SOCIOECONOMIC STATUS BUT IT IS
AN IMPORTANT POINT TO ADDRESS.
AND WITH YOUR PERSPECTIVE
YEARS INCLUDING AS UNIVERSITY
PRESIDENT, YOU WANT TO COMMENT
ON THIS?
>>YES, IT IS ACTUALLY AN
EXCELLENT POINT.
TYPICALLY THESE DAYS WHEN YOU
TALK ABOUT DIVERSITY AND I
GUESS AS A PHYSICIAN AND MY
VIEW, WE DO TALK ABOUT THE
FIRST GENERATION AND THE
PIPELINE.
THAT IS ONE DIMENSION THAT YOU
CAN ACTUALLY TARGET AND IT
DOES HAVE THOSE LIKE
DOWNSTREAM EFFECTS THAT CAN
IMPACT THEIR FAMILY, THEIR
COMMUNITY AND THERE ARE OTHER
PIECES OF IT BUT IT IS ANOTHER
PIECE OF THE FACTORS.
WE HAVE GOT TEN AWAY FROM
DIVERSITY IN UNIVERSITIES AND
SAY WELL IT IS 15 PERCENT
HERE, 20 PERCENT THAT AND I
BET YOU WITH SOME OF THE
UNIVERSITY HIRES YOU HAVE, YOU
HAVE THE ONES THAT NEVER GET
HIGHLIGHTED.
WHEN WE THINK OF IT AS THE
COLLEGE LEVEL OF STUDENTS IN
THE PIPELINE, THAT IS ONE OF
THE CRITICAL PIECES BECAUSE
THEY FALL OUT OF PIPELINE
OFTEN BECAUSE THEY DON'T HAVE
THE FINANCIAL SUPPORT OR
MENTOR AND THAT COULD BE A
CHARACTERISTIC THAT COULD HELP
BROADEN DIVERSITY IN GENERAL.
>>OTHER QUESTIONS?
YEAH.
OKAY, THANK YOU.
>>YOU KNOW ONE OF THE AREAS
THAT WE ARE HEARING A LOT
ABOUT IS ARTIFICIAL
INTELLIGENCE AND MACHINE
LEARNING AND ITS APPLICATIONS
TO BIOMEDICAL SCIENCE.
ALL ARE OPPOSITION OF COURSE
AND THERE ARE SO MANY LEADING
SCIENTISTS IN JOURNALS AND
OTHER AREAS TALKING ABOUT THE
BENEFITS THAT WILL COME OUT OF
IT BUT ALSO A COMPLEX ISSUE
OF --
[INDISCERNIBLE]
GIVEN THE DECADES OF RESEARCH
THAT NIA HAS DONE AND CREATED
HUGE DATA SETS OF ALL KINDS
AND BY DEPOSITORIES, MONTHS OF
STUDIES, I WONDER FOR IT IS
TIME FOR US TO THINK ABOUT A
COALITION TO CREATE A CENTRAL
RESOURCE AT NIA ON AI
ADDRESSING THE RISKS AND
ADVANTAGES LINKED WITH IT AND
THAT COULD BE PROVIDED AS A
SERVICE IN SOME WAYS TO THE
INVESTIGATORS WHO MAY NOT HAVE
RESOURCES OR A CHANCE TO
UTILIZE THE AMAZING
CONTRIBUTIONS IN ARTIFICIAL
INTELLIGENCE --
[INDISCERNIBLE]
AND YOU NAME IT.
SO I WONDER IF ANY THOUGHT HAS
BEEN GIVEN IN THAT AREA OF
CREATING A CENTRAL DATA SOURCE
FOR NIA SCIENTISTS?
>> THANK YOU FOR THAT
QUESTION, VERY IMPORTANT.
AT THE NIH AND VERY MUCH AT
THE NIA LEVEL, WE HAVE ACTIVE
WORK GROUPS THAT TRANSCEND,
ALL OF OUR POSITIONS,
INTRAMURAL AND EXTRAMURAL
AROUND AI AND LOOKING AT THESE
POLICIES.
I DON'T KNOW YET IF WE ARE AT
THE POINT OF YOUR VERY
INTERESTING SUGGESTION,
TRANSPORTING IT TO A RESEARCH
CENTER BUT SOMETHING TO LOOK
AT AND CONSIDER AND A FAIR
POINT, TO THINK WHERE WE ARE
AND APPROPRIATE LEVEL, IF
THERE IS A ROLE FOR ACTUALLY
FUNDING OR SUPPORTING SOMEHOW
A CENTRAL RESOURCE FOR THIS.
>> THOSE CENTERS COULD BE
CREATED AT SOME INSTITUTIONS
AND NIA COULD SUPPORT IT,
EITHER WAY BUT THIS IS
SOMETHING THAT COULD BE VERY
USEFUL FOR THE FIELD.
>>YEAH, HEARING THIS, MAYBE A
TOPIC OF INTEREST IN ONE OF
OUR FUTURE COUNCIL MEETINGS
THAT WE COULD HAVE A REPORT
BACK FROM THE CORE GROUP AT
NIA THAT ARE DEALING WITH IT
AND YOU COULD OFFER YOUR
FURTHER INPUT.
>>ALL RIGHT, ANY LAST
QUESTIONS?
ALL RIGHT, THANK YOU VERY MUCH
FOR THOSE DISCUSSIONS AND
THANK YOU Dr. HODES FOR YOUR
DIRECTOR'S REPORT.
WE WILL MOVE ON.
THE NEXT AGENDA ITEM IS THE
REPORT ON THE TASK FORCE ON
THE AGING RESEARCH.
THE CHAIRS OF THIS
SUBCOMMITTEE, Dr. JENNIFER
MANLY AND Dr. CRUZ.
Dr. CRUZ WILL START US OFF.
>>GOOD MORNING AGAIN.
AFTER THE HEALTHY RESEARCH
SECTION YESTERDAY AND STARTING
WITH THAT, WE HAD THREE GUEST
SPEAKERS.
WE STARTED WITH Dr. ROBERT
GREEN WHO THEN MOVED ON TO
Dr. SIMPSON'S VIDEO AND THE
LAST PERSON WAS MISS JOY
TOLLIVER.
SO JUST SOME QUICK HIGHLIGHTS
ON Dr. ROBIN GREEN'S
PRESENTATION, HER FOCUS WAS
STRATEGIES FOR EFFECTIVELY
ENGAGING WOMEN OF COLOR INTO
CLINICAL TRIALS.
AND SO Dr. GREEN'S COMMENTS
WERE PRIMARILY BASED ON THIS
STUDY WHICH IS A MAJOR
PERSPECTIVE LONGITUDINAL STUDY
ON THE NATIONAL HISTORY OF
MENOPAUSE AND DECLINING
FUNCTION.
THE STUDY INVOLVES SEVEN
CLINICAL SITES ACROSS THE
NATION, RECRUITING WOMEN FROM
DIVERSE, ETHNIC AND RACIAL
GROUPS, SENATOR SOCIOECONOMIC
STATUS, REGIONS AND REGIONS OF
THE COUNTRY..
THIS OF COURSE IS
REPRESENTATIVE OF
AFRICAN-AMERICAN WOMEN,
CHINESE, JAPANESE, HISPANIC
AND CAUCASIAN WOMEN.
IT HAS ENROLLED OVER 3302
WOMEN AT SEVEN SITES.
AND HER TALK WAS LOOKING AT
THE EFFECTIVE STRATEGIES BASED
ON HER WORK.
SHE HIGHLIGHTED THE
RECRUITMENT STRATEGY THAT SHE
THINKS HAS BEEN USEFUL IN
REACHING AND ENGAGING DIVERSE
POPULATIONS SO SHE TALKED
ABOUT, YOU KNOW, USING CENSUS,
UTILITY RECORDS, VOTER
REGISTRATION, TELEPHONE
DIRECTORY AND ALSO RACIAL AND
ETHIC ORGANIZATION MEMBERSHIP
MECHANISMS OF ENGAGING,
CONNECTING, MOBILIZING
POTENTIAL PARTICIPANTS FOR
THIS STUDY.
SHE TALKED ABOUT THE
IMPORTANCE OF USING MULTIPLE
RECRUIT RECRUITMENT STRATEGIES
SUCH AS SNOWBALLING WHERE
RECUTES WERE ASKED TO
RECOMMEND OTHERS.
Dr. GREEN ALSO EMPHASIZED
THE IMPORTANCE OF THE SILO
PIECE IN TRANSPORTATION TO
EFFECTIVELY ENGAGE
PARTICIPANTS, PROVIDING
TRANSPORTATION FOR EXAMPLE IS
IMPORTANT PARTICULARLY IN
DIVERSE POPULATIONS.
SHE ALSO ADDRESSED PORTIONS OF
BEING INTENTIONAL ABOUT
FOCUSING ON RESEARCH ON HEALTH
INTERESTS TO THE POPULATION
BEING TARGETED.
WHEN CONDUCTING DISPARITY,
HIGHLIGHTED BEING CULTURALLY
COMPETENT.
AN EXAMPLE, SUCH AS ALLOWING
FAMILY MEMBERS TO ACCOMPANY
PARTICIPANTS WITH ACCESS IN
THE CLINE AND ACKNOWLEDGE THE
IMPORTANCE OF FAMILY IN THE
PROCESS.
PROVIDING FLEXIBLE SCHEDULING
AND REMUNERATION AND SHE
THOUGHT THAT WOULD BE
IMPORTANT.
AND THEN HIGHLIGHTED
TRANSFORMATION OF LITERACY --
TRANSLATION AND LITERACY.
IN THIS ONE CLINIC, THEY HAVE
TRANSLATED ALL THE MATERIAL.
AND SHE MENTIONED THE SITE
STAFF COMING FROM COPIOUS
RACIAL GROUPS, SPEAKING THE
LANGUAGES REPRESENTED IN THE
STUDY PARTICIPANTS AND ARE
KNOWLEDGEABLE OF CULTURAL
CUSTOMS.
SHE ALSO SPOKE ABOUT THE
IMPORTANCE OF TRANSPARENCY AND
MAKING CONTACT WITH STUDY
PARTICIPANTS INCLUDING
PROVIDING RESULTS FOR MANY
EDUCATORS OF WELLNESS AND
ALERT FOR INDICATORS OF
POTENTIAL UNDERLYING DISEASE.
AND SHE ALSO URGED RESEARCHERS
TO LOOK THROUGH AN AGING LIST,
THAT PARTICIPANTS MAY NEED
MORE ASSISTANCE.
LARGER FONT, FOR EXAMPLE, FOR
READING THE MATERIAL.
SO Dr. GREEN SUGGESTED A
DIVERSE STUDY FOR THE DIVERSE.
AND THEN NEXT WE HAD Dr.
JOHNSON WHO TALKED ABOUT
OUTREACH THOSE AFFECTED BY
COVID-19 PANDEMIC AND VACCINE
AND THERAPEUTIC TRIALS.
Dr. MASON INDICATED THE
CRITICAL TOOLS IN HEALTH
DISPARITIES AND ARE WHEN
CONDUCTED CORRECTLY, RESEARCH
PROCESS FUNDING AND POTENTIAL
INTERVENTIONS TO ADDRESS
HEALTH DISPARITIES RESONATES
AND BENEFITS THE COMMUNITY.
IN THE CASE OF THE FOCUS, THEY
ARE LOOKING AT NATIVE
AMERICAN, ALASKA NATIVE, ASIAN
HAWAIIANS AND PACIFIC
ISLANDERS.
THE OBJECTIVES OF THE APPEAL
ARE, ONE, TO CONDUCT COMMUNITY
RESEARCH AND FOCUSED AWARENESS
AND EDUCATION TO ADDRESS
WIDESPREAD MISINFORMATION AND
DISTRUST WITH REGARD TO
COVID-19 AND PROVIDE EVIDENCE
BASED RESPONSE TO THE DISEASE.
SECOND, FACILITATED
INCLUSION --
[INDISCERNIBLE]
AND THERAPEUTICS.
SOME OF THE ACTIVITIES DONE BY
THE TEAMS INCLUDE ESTABLISHED
REPRESENTATION OF COMMUNITIES,
ESTABLISHED REPRESENTATION,
INCREASED TRUST IN SCIENCE AND
INTERVENTION.
THE DOCTOR TALKED ABOUT
LESSONS LEARNED FROM THIS
EXPERIENCE.
FIRST THAT LEADERSHIP HAS A
DIFFERENT LENGTH.
LOCAL GOVERNMENT OFFICIALS,
FAITH LEADERS ARE INS.
AL TO REACH A COMMUNITY IN
EFFECTIVE WAYS SO WE NEED TO
WORK WITH THEM.
COLLABORATION AND CULTIVATION
WITH COMMUNITY PARTNERS.
COMMUNITY INCREASES THE
EFFECTIVENESS OF ENGAGEMENT,
WORKING IN COLLABORATION WITH
LOCAL COMMUNITY ORGANIZATIONS.
RACE, ETHNIC DATA ARE CRITICAL
TO THE COVERAGE OF DISPARITIES
IN EXISTING DATA.
HAVING MULTIPLE LANGUAGES IS
CRITICAL TO THE COMMUNITY.
SPECIFIC DEMANDS FOR EXPERTISE
IN COMMUNITY ENGAGEMENT AND
RESEARCH.
AND THEN FINALLY WE HEARD FROM
MS. DORIS TOLLIVER AND SHE
HIGHLIGHTED THE NIH STARTUP
TALENT FOSTERING
ENTREPRENEURIAL WITH DIVERSITY
AND HIGHLIGHTED THE NIH SMALL
BUSINESS PROGRAM AND
INDICATING THAT IT PROVIDES
MORE THAN $140 MILLION IN
USING DEVELOPMENT GRANTS TO
SMALL BUSINESSES, THROUGH THE
SMALL BUSINESS INNOVATION
RESEARCH, FBI R AND SMALL
TRANSFERS PROGRAMS.
TO DEVELOP INNOVATION TO
ADDRESS INFO RELATED
CONDITIONS.
AND THE PROBLEMS ADDRESSES
HERE THROUGH THE EFFORTS AT
PERSISTENT LOW LEVELS OF NIH.
AND FOCUS ON WOMEN AND
MINORITIES IS VERY LOW SO
HOPEFULLY THROUGH THIS
PROGRAM, WE WILL MAKE A
DIFFERENCE IN THAT SPACE.
MS.TOLLIVER HIGHLIGHTED NIH'S
APPLICATIONS OF THE PROGRAM
AND PROGRAMS OFFERING NIH FBI
R LEVEL 1 APPLICATIONS
SUBMITTED BY UNDER REPRESENTED
SMALL BUSINESSES THAT ARE
COMPLIANT AND RESPONSIVE TO
THESE CRITERIA.
IT WAS ALSO INDICATED THAT NIH
HAS AS ITS GOAL TO FOSTER
DIVERSITY IN ITS RESEARCH,
INNOVATION AND
ENTREPRENEURSHIP AS WELL AS
GOALS TO INCREASE SDI R&D IR
TO EFFECT SMALL BUSINESSES AND
WOMEN-OWNED SMALL BUSINESSES.
THIS HAS THE POTENTIAL OF
PROVIDING STRATEGIC RESOURCES
TO ENTREPRENEURS WITH
INNOVATIVE IDEAS FOR RESEARCH
TECHNOLOGY FOR ALL PRODUCTS
THAT WILL FURTHER RESEARCH AND
DEMONSTRATION AND THE TALENT
TO ACCELERATE THEIR IDEAS.
MOVING FORWARD, THE 2023NIH
CHALLENGE WILL BE LAUNCHED --
[INDISCERNIBLE]
>> A COUPLE OF POINTS.
ONE IS THE FIRST TWO TALKS
THAT SUMMARIZE VERY WELL JUST
NOW WERE REALLY ABOUT
INTENTIONA L INVESTMENTS IN
THE COMMUNITIES THAT YOU ARE
TRYING TO REACH.
AND HOW IMPORTANT TRUST, A
MUTUAL TRUST WAS IN ENGAGEING
INVOLVEMENT AND THEY WERE VERY
SUCCESSFUL, FOR EXAMPLE.
WE WANTED TO BRING THOSE TWO
TO COUNCIL IN PART BECAUSE,
YOU KNOW, AS WE DISCUSSED,
ALZHEIMER'S DISEASE AND
RELATED DEMENTIA RESEARCH IS
VERY MUCH AN EMPHASIS IN NIA
RIGHT NOW BUT HAVING A NUMBER
OF CHALLENGES IN RECRUITMENT
ACROSS DIFFERENT RACIAL AND
ETHNIC AND SOCIOECONOMIC
GROUPS, HAVING A LOT OF
TROUBLE IN CLINICAL TRIALS.
IN SOME CLINICAL TRIALS, YOU
KNOW, HAVING PARTICIPATION
FROM COMMUNITIES THAT FROM
DISPROPORTIONATELY AFFECTED BY
COGNITIVE IMPAIRMENT.
AND SO THESE SUCCESSFUL
EXAMPLES REALLY SHOWS THE TYPE
OF INVESTMENT THAT IS NEEDED
IN ORDER TO INCREASE
PARTICIPATION.
AND THEN I THINK WITH THE --
THE STARTUP CHALLENGE, AGAIN,
REALLY BUILDING CAPACITY FOR
THE TYPE OF SCIENCE THAT IS
REALLY GOING TO MOVE IT
FORWARD IN A VERY RIGOROUS
WAY, THE INCLUSIVE -- AN
INCLUSIVE WORKFORCE AS WELL AS
AN INCLUSIVE PARTICIPATION, IS
YOU KNOW THE BASIS OF A
RIGOROUS SCIENCE AND
INNOVATION.
SO I THOUGHT THESE WERE
WONDERFUL EXAMPLES AND THANK
YOU FOR ALLOWING US TO TALK
TODAY.
>>THANK YOU VERY MUCH,
DOCTORS CRUZ AND MANLY FOR THE
OVERVIEW OF THE TASK FORCE
PRESENTATION.
ANY FURTHER COMMENTS OR
QUESTIONS FROM COUNCIL MEMBERS
ON THOSE PRESENTATIONS?
>>I ALMOST DUMPED MY WATER.
I THOUGHT THOSE WERE REALLY
WONDERFUL, SORT OF SUCCESSFUL
RECRUITMENT STRATEGIES SO I
THINK THIS WILL END UP BEING A
TWO-PART QUESTION.
THE FIRST IS HAS NIH ATTEMPTED
TO CAPTURE THIS IN A MORE
COMPREHENSIVE LOOK AT
RECRUITING RESEARCH ACROSS
PROJECTS AND IF NOT, IS THAT
SOMETHING NIH SHOULD BE
ASSESSING?
THE SECOND AND WHAT I THINK
ARE ADDITIONAL CHALLENGES FROM
NIARD, FAMILY FACTORED IN AND
THESE WERE REALLY SUCCESSFUL
PROGRAMS THAT PEOPLE IN
GENERAL COULD GET THERE ON
THEIR OWN TWO FEET WHEN
TRAVELING DOWNTOWN.
SO HOW COULD YOU PRIORITIZE
CAREGIVERS, UNLICK ME WHO
COULD SUPPORT MYSELF AND TAKE
CARE OF THE PEOPLE I AM TAKING
CARE OF VIA PHONE AND STILL DO
MY JOB, HOW ARE WE THINKING
ABOUT OR SHOULD WE BE THINKING
ABOUT CIRCULAR TO OUR HOURLY
WAGE WORKERS WHO DON'T HAVE
THE LUXURY HAD LUXURY THAT I
HAD TAKING CARE OF MOM THROUGH
A PERIOD OF TIME AND SHOULD WE
BE THINKING ABOUT THAT FOR THE
NEXT GENERATION OF
GERI-GENETICS?
>>JENIN, YOU WANT TO ADDRESS
THE SECOND QUESTION ON
CAREGIVERS FIRST AND THEN I
COULD PROBABLY CHIME IN
DETERMINING WHAT THE NIH
EFFORTS ARE GIVEN THE EXAMPLE.
>>WELL, I AM NOT GOING TO BE
ABLE TO SPEAK TO ALL CARE
GIVING RESEARCH SUPPORTED BY
NIA BUT SOME OF THE PROGRAM
STAFF MIGHT BE ABLE TO ADD TO
THIS.
I DO THINK WE ACTUALLY, YOU
KNOW, IN THIS ROOM YESTERDAY
WERE DISCUSSING, YOU KNOW SOME
POTENTIAL WAYS OF REACHING OUT
TO CAREGIVERS AND ENGAGING
CAREGIVERS WHERE THEY ARE IN
THEIR HOMES, REMOTELY.
AND I ACTUALLY THINK DUE TO
THE PANDEMIC, WE HAD SOME OP
OPPORTUNITIES TO BE CREEP
UNITIVE ABOUT THAT.
OVER THE PHONE OR YOU KNOW
PROVIDING -- I KNOW THERE ARE
A NUMBER OF STUDIES PROVIDING
PEOPLE WITH DEVICES AND
INTERNET ACCESS IN ORDER TO
INCREEPS THAT COMMUNICATION.
AND YOU KNOW ESSENTIALLY FOR
MOTHERS, THERE ARE TOOLAS THAT
ARE, YOU KNOW -- WHO ARE
GUIDING PEOPLE THROUGH THE
BIRTH PROCESS BUT FOR
CAREGIVERS, THERE COULD BE
ESSENTIALLY EQUIVALENT
LENGTHS, RIGHT, PEOPLE WHO ARE
GUIDING CAREGIVERS THROUGH THE
PROCESS AND, YOU KNOW THEY
PROVIDE A BRIDGE BETWEEN THE
SERVICES THAT ARE OUT IN THE
COMMUNITY AND WHAT'S GOING ON
IN THE HOME AND IT IS
CULTURALLY INFORMED WAY.
>>THANKS FOR THAT QUESTION.
AND I THINK FOR SURE CARE
GIVING IS A KEY ISSUE RIGHT
NOW FOR OUR NATION AND OUR
OLDER ADULTS.
THERE IS VERY STRONG INTEREST
AS YOU KNOW FROM THE
ADMINISTRATION RIGHT NOW SO WE
HAVE THAT RESOURCE AND
ATTENTION THAT IS IMPORTANT TO
LEVERAGE.
I THINK THERE IS VERY BILL
KNOWLEDGE AROUND CARE GIVING.
FOR EXAMPLE, IN SOME DIVERSE
POPULATIONS, IN THE HISPANIC
SPACE, FOR EXAMPLE, MANY
CAREGIVERS DON'T SELF-IDENTIFY
AS CAREGIVERS AND THAT ALONE
IS A HUGE CHALLENGE BECAUSE IF
THEY DON'T THINK THEY ARE
CAREGIVERS, HOW WILL THEY LOOK
FOR RESOURCES, ASK FOR HELP?
SO I AM GLAD YOU BROUGHT THAT
UP AND I THINK IT IS AN
IMPORTANT ISSUE TO ADDRESS.
>>MAY I JUST FILL IN THAT, I
THINK WE NEED TO CONSIDER
THOSE WHO ARE LIVING ALONE
WITH ALZHEIMER'S AND RELATED
DEMENTIAS AND I DON'T KNOW THE
CURRENT STATISTICS BUT THERE
ARE QUITE A NUMBER.
FOR FOLKS, HOW DO WE PROVIDE
SUPPORT AND SERVICES AND
MOBILIZE THE RESOURCE
NECESSARY TO SUPPORT PEOPLE
WHERE THEY ARE AND HELP THEM
AS THE DISEASE PROGRESSES.
>>JUST AS A FOLLOW UP TO THAT
COMMENT, AND I THINK IT IS SO
TRUE, AND CERTAINLY PART OF
THE DISCUSSION IN WISCONSIN,
THE ONE THING WE HAVE LEARNED
IN UNDER REPRESENTED
COMMUNITIES FOR OVER A DECADE
NOW FROM THE OAT SIDE, VERY
FORTUNATE TO HAVE A LARGE
COHORT OF NATIVE AMERICANS AND
AFRICAN-AMERICANS DOING
RESEARCH FOR US BUT OVER THAT
TIME AS Dr. MANLY MENTIONED,
IT TAKES TIME TO DEVELOP THEIR
TRUST.
BUT AT THE SAME TIME, IT IS
WELL-KNOWN TO PROVIDE SERVICE
TO THEM AND THE SERVICE WE
HAVE DONE, SUCH AS COMPUTER
CLASSES, FOOD, THE PEOPLE LIKE
THAT.
SO THOSE KIND OF ONGOING
SERVICES MAKE THE COMMUNITY
FEEL YOU ARE NOT JUST THERE TO
DO RESEARCH BUT PROVIDING YOUR
TIME AND THEY NEED HELP ON AN
ONGOING BASIS WHETHER YOU ARE
DOING RESEARCH OR NOT.
AND I THINK THAT IS VERY
HELPFUL AND DOES GET MORE
STRENGTHENED THAT WE ARE THERE
TO HELP YOU BUT IT HAS TO BE
ON AN ONGOING BASIS AS FAR AS
RESOURCES AND YOU CAN GET IT,
YOU KNOW, FROM DIFFERENT MEANS
BUT THEN ALL OF THE SERVICES.
>>YOU KNOW JUST OUT OF
CURIOSITY, I DON'T THINK I
FORMULATED MY QUESTION AS WELL
AS I THOUGHT I DID WHICH IS
KIND OF THE NEED FOR
CAREGIVERS AS YOUR DEMENTIA
PROGRESSES, THAT IN AND OF
ITSELF A BARRIER TO
PARTICIPATION IN RESEARCH?
AND THAT IS REALLY WHERE I WAS
KIND OF GOING WITH THAT
QUESTION.
I WAS WONDERING LIKE FROM YOUR
DIRECT EXPERIENCE, DO YOU SEE
THAT AS A BARRIER TO ACTUALLY
ENROLLING PEOPLE IN THE STUDY
SO I THINK THAT IS WHAT I WAS
TRYING TO IMPRESS US TO THINK
ABOUT, SORT OF THE, YOU
KNOW -- SO HAVING A CAREGIVER
WHO IS UNABLE TO HELP YOU TO
PARTICIPATE IN RESEARCH AND
WHETHER THERE IS THINGS YOU
CAN DO AND THEN FURTHER TO THE
POINT ABOUT LIVING ALONE, THAT
IS ALSO CAN BE A BARRIER TO
PARTICIPATING IN RESEARCH, SO
IT IS DOUBLE-EDGED FOR THIS
NEXT GENERATION --
[INDISCERNIBLE]
>>AND NOT ONLY FOR
ALZHEIMER'S RIGHT?
I THINK THE HEALTH IN TIME
SURVEY MIGHT BE USEFUL TO FIND
OUT HOW THEY HANDLE THAT.
I MEAN WE HAVE A LOT OF
SURVEYS OUT THERE WITH FOLKS
PARTICIPATING IN STUDIES.
IT IS NOT A NEW THING FOR NIA.
BUT WHETHER OR NOT IT HAS BEEN
WISDOM COLLECTED IN ONE PLACE,
THAT COULD THEN BE RESOURCED
FOR OTHERS, I DON'T KNOW THAT
THAT'S BEEN DONE.
>>AND JUST FOR EVERYONE'S
INFORMATION, WE JUST HOSTED A
LARGE SUMMIT, A 3-DAY SUMMIT
AT THE END OF MARCH OF THIS
YEAR ON CARE SERVICES SUPPORT
FOR PERSONS LIVING WITH DEMENT
SHALL AND THEIR CARE PARTNERS
AND CAREGIVERS SO A REPORT ON
THAT WILL BE COMING OUT
SHORTLY SO STAY TUNED FOR THAT
TOO, WHICH HAD A LOT OF REALLY
VALUABLE INFORMATION IN THIS
PARTICULAR ROUND.
>>ALL RIGHT, THANK YOU AND I
WANTED TO FOLLOW UP ON NANCY'S
POINT AND ALSO PUT IN A
REQUEST IF THIS COULD BE AN
AGENDA ITEM AT A FUTURE
MEETINGS.
I THINK NOT ONLY FOR DEMENTIA
PATIENTS, A LOT OF OLDER
PATIENTS, IF THEIR FAMILY
MEMBERS CAN'T ACCOMPANY WITH
THEM, PARTICIPATE WITH THEM,
TRANSPORT THEM, THEY CAN'T
PARTICIPATE IN STUDIES, EVEN
WITHOUT COGNITIVE IMPAIRMENT
AND IT TENDS TO BE AFTERNOON
MORE SO IN UNDER REPRESENTED
POPULATIONS, EITHER BECAUSE OF
DISTRUST OR LANGUAGE ISSUES OR
CULTURAL ISSUES, IT IS JUST
REALLY AN ISSUE AND ON TOP OF
THAT, IRBS WON'T RECOGNIZE THE
NEED TO PAY ADDITIONAL
INCENTIVE FOR BOTH THE PATIENT
AND THE CAREGIVER AND THE
TRANSPORTATION COST OF THE
CAREGIVER AND PERHAPS CHILD
CARE COSTS FOR THE CAREGIVER
WHO IS OFTEN, YOU KNOW, TAKING
CARE OF CHILDREN OR
GRANDCHILDREN AND SO THIS
ISSUE OF THE NEED FOR UNEQUAL
INCENTIVES, IT IS A HUGE ISSUE
AND I AM WONDERING IF IT IS
ONE WE COULD EVEN ADDRESS WITH
OHIT OR HAVING A BROADER
DISCUSSION.
BECAUSE I THINK THAT IS A HUGE
ISSUE TO BE ADDRESSED TO BE
INVOLVED IN OUR STUDIES.
>>GREAT SUGGESTION, THANK YOU
SHARON.
WE MADE NOTES.
>>I WANT TO BACK THAT UP
STRONGLY.
THIS HAS BEEN IN THE AIDR
WORLD, I HAVE BEEN ON THAT
BANDWAGON BY REQUIRING THERE
TO BE A STUDY PARTNER, WE ARE
EXCLUDING A HUGE NUMBER OF
PEOPLE WHO COULD BE IN OUR
STUDY AND THEY HAVE GOOD
ARGUMENTS FOR HAVING THEM, TO
GET BETTER DATA ON PEOPLE,
ESPECIALLY ONCE THEY ARE
IMPAIRED, YOU GET BETTER DATA
FROM SOMEONE TELLING THEM
SOMETHING SO WE UNDERSTAND
THAT BUT WE SHOULD BE USING
TECHNOLOGY, OTHER THINGS WE
CAN USE TO GET ANSWERS TO
THOSE QUESTIONS.
I DON'T THINK WE SHOULD
EXCLUDE THEM AND SAY YOU LIVE
ALONE, YOU ARE AN OLDER ADULT,
YOU CANNOT BE IN OUR STUDY AND
NOT TO PUT ANYBODY ON THE SPOT
BUT THEN INCENTIVE PROGRAMS,
WE ARE REQUIRED TO GET STUDY
PARTNERS ON OUR PARTICIPANTS,
REQUIRED.
SO PEOPLE WHO DON'T HAVE -- SO
IN OUR COHORTS, PEOPLE WHO
DON'T HAVE SOMEBODY ALREADY
AWHO HAS SIGNED AN AGREEMENT
FOR THE STUDY, THOSE ARE THE
ONLY PEOPLE WE CAN GO TO FOR
ENROLLMENT IN OUR STUDY.
SO THERE ARE PEOPLE WE DON'T
WANT TO EXCLUDE AND THERE ARE
GOING TO BE THOSE OLDER PEOPLE
WHO ARE ALONE IN THE COMMUNITY
SO THANK YOU FOR THAT.
>>SUSAN?
>>ONE OTHER THING TO THINK
ABOUT IN A SENIOR COMMUNITY
WHERE THEY HAVE ALZHEIMER'S
UNITS, THEY HAVE PEOPLE THERE
ACTUALLY RELATIVELY
INDEPENDENT IN ASSISTED
LIVING, SO THEY HAVE A WHOLE
GROUP.
THE RESEARCH CAN BE BROUGHT TO
THEM SUCCESSFULLY SO THEY
DON'T HAVE TO GO OUT OF WHERE
THEY ARE LIVING BUT THEY CAN
PARTICIPATE.
NOW CERTAIN THINGS CAN BE
DONE, LIKE MAYBE A MRI, BUT
THERE ARE A LOT OF TESTING
THAT CAN BE DONE ON THE
OUTSIDE.
FURTHERMORE, THOSE WITH
ASSISTANCE WITH IT, THEY ARE
ABLE TO BRING ELECTRONIC
EQUIPMENT OR WHATEVER THEY
NEED, TESTS, OUT TO THE
COMMUNITY.
SOMETIMES IT CAN BE DONE IN
CENTERS, CHURCHES, YMCAS, WE
CAN GET ASSISTANCE THERE
RATHER THAN HAVING TO COME IN
FROM OTHER AREAS.
>>I SPEAK FROM EXPERIENCE?
A. MY MOTHER PASSED AWAY LAST
YEAR, SUFFERED FROM
ALZHEIMER'S FOR ABOUT FOUR
YEARS.
WE ALREADY KNEW SHE HAD
DEMENTIA AND DIDN'T RECOGNIZE
IT BUT LET ME TELL YOU TO
RESEARCH WAS FARTHEST FROM MY
MIND WITH ME AND MY OTHER FIVE
SIBLINGS.
WHAT WAS PRIMARY IN OUR MIND
WAS TO FIND WAYS TO ADMINISTER
TO HER.
AND THIS OTHER GROUP OF
FINDING RESOURCES WITHIN NIA
WAS NEVER ON OUR MIND.
WE ONLY DEALT WITH HER PCD AND
OCCASIONALLY ANOTHER RESOURCE
BUT NONE OF THEM EVER
MENTIONED ANYTHING ABOUT HEY
THERE IS THIS STUDY AND --
[INDISCERNIBLE] [INAUDIBLE].
NONE OF THAT HAPPENED.
O.
>>THANK YOU FOR THAT.
>> ONE VERY BRIEF COMMENT,
TALKING ABOUT RESOURCES, YOU
COULD GO TO RESOURCES TO GET
FUNDS AND SUPPORT, IN CAN YOU
SAYING REHAB, WE HAVE BEEN
WORKING WITH THE GOVERNOR'S
OFFICE, STATE GOVERNMENT
BECAUSE THEY ARE SUPPOSED TO
TAKE CARE OF PEOPLE WITH
DEMENTIA.
SO THE FIRST LADY OF WISCONSIN
AND THE GOVERNOR ARE GOING TO
HOST AN EVENT AT THEIR OWN
RESIDENCE INVITING THE LOCAL
MEDIA TO DRAW ATTENTION ON
CARE GIVING AND ALSO THE HOPE
IS JUST THAT THE STATE
GOVERNMENTS WILL HAVE FUNDS
RELATED TO THIS AREA SO I
THINK THAT THERE ARE OTHER
PEOPLE IN THE STATE WORKING
WITH STATE GOVERNMENT THAT
COULD BE QUITE USEFUL AND THEY
HAVE A INTEREST IN THIS
BECAUSE THEY HAVE PEOPLE WHO
ARE SUFFERING.
>>ABSOLUTELY.
THANK YOU ALL FOR THESE VERY
VALUABLE COMMENTS, TOO, AND I
ASSURE YOU PAUSE WE DID HOST A
DIFFERENT SUMMIT RECENTLY,
THIS IS A HIGH PRIORITY FOR
THE INSTITUTE TOO AND THERE
ARE CERTAINLY RESEARCH BEING
DONE IN THIS AREA AND MORE TO
COME FOR SURE, TOO, BECAUSE
OBVIOUSLY IT HAS BEEN -- WE
HAVE HEARD THIS FROM THE
COMMUNITY AND JOHN, YOU CAN
COMMENT, TOO ON --
>>I WOULD COMMENT, RESEARCH
FOR A WIDE RANGE OF THESE
AREAS ON MULTITUDE TOPICS BUT
ONE THING I WANT TO
PARTICULARLY POINT OUT LAST
MARCH ABOUT NHAS STUDY WHICH
HAS NOW INCREASING AMOUNT OF
DATA NOT JUST ABOUT THE
MEDICARE POPULATION BUT
ACTUALLY TESTING A NUMBER OF
THEM SO HOPEFULLY CAN GET MORE
INTO THESE PLACES --
[INAUDIBLE]
>>THANK YOU, JOHN AND THEN
JUST CIRCLING BACK TO ONE OF
YOUR ORIGINAL QUESTIONS OF
WHAT WE'RE TRYING TO DO WITH
THESE VALUABLE PRESENTATIONS
WE HAD GOING TO THE CHANCE
BOARD ABOUT LESSONS LEARNED IN
RECRUITMENT THEN TOO AND YES,
THIS IS THE REASON WE BROUGHT
THIS FORWARD TOO IN THE TASK
FORCE PRESENTATION BECAUSE IT
IS A REAL SUCCESS STORY AND
MODEL FOR HOPEFULLY LESSONS
LEARNED FOR THE REST OF OUR
COMMUNITY.
SO WE'RE TAKING THOSE
COMMENTS, YOU KNOW SERIOUSLY
AND REALLY LOOKING MORE INTO
COMMUNITY BASED RESEARCH AND,
YOU KNOW, OTHER STRATEGIES FOR
RECRUITMENT AND THIS IS
SOMETHING THAT WE ARE GOING TO
MONITOR CLOSELY IN OUR
CLINICAL RESEARCH OFFICE NOW
AND WHEN WE SEE THAT THERE ARE
-- BECAUSE OF OUR CROEM
SYSTEM, WE CAN VISUALIZE WHEN
PEOPLE ARE FALLING BEHIND IN
RECRUITMENT AND TRY TO
UNDERSTAND WHY AND STEP IN AND
HELP BECAUSE WE HAVE A LOT OF
THIS INFORMATION AT OUR
FINGERTIPS, TOO.
WE CAN LINK PEOPLE TO OTHER
GROUPS TOO IN MANY WAYS AND
HOPE THIS CAN MAKE OUR TRIALS
MUCH MORE SUCCESSFUL BUT EVEN
WHEN TRYING TO DO PREVENTION
TOO, WHEN THESE REPORTS COME
IN, WEAR' REALLY ENGAGING OUR
RESEARCHERS TO ENSURE TEASE
TYPE OF STRATEGIES ARE FLESHED
OUT AND UNDERSTOOD AND HOPE
FOR SUCCESS IN OUR TRIAL
RESEARCH TOO SO DOING A LOT OF
DIFFERENT AVENUES OF HELPING
OUR COMMUNITY AS MUCH AS
POSSIBLE IN THESE AREAS.
BUT WE UNDERSTAND, TOO, THAT
THIS IS NO EASY TASK AND WE DO
NEED TO THINK ABOUT BUILDING
INFRASTRUCTURE IN THESE AREAS
TOO TO HELP OVERALL THE
COMMUNITY TOO AND THAT IS ON
THE HORIZON FOR SURE, TOO,
BESIDES WHAT WE HAVE ALREADY
DONE BUT WE KNOW THERE IS
STILL A LOT MORE TO COME.
ALL RIGHT, WE CAN THEN MOVE ON
TO OUR NEXT REPORT ON THE
WORKING GROUP ON PROGRAM AND
OUR CHAIR IS Dr. SUSAN
GREENSPAN SO SUSAN?
>>THANKS, KEN.
SO I THINK FIRST WE WILL START
WITH A CONCEPT THAT WE
DISCUSSED, THE CONCEPT WAS
ENTITLED TECHNOLOGY TO
FACILITATE CHARACTERIZATION OF
THE UNDER RESOURCED POPULATION
FOR ADRD STUDIES.
DOCTOR LONGO WAS THE PRIMARY
REVIEWER AND Dr. RUBEN WAS
THE SECONDARY VIEWER.
DOCTOR LONGO IF YOU COULD
PLEASE SUMMARIZE THE CONCEPTS
AND DISCUSSION?
>>SURE, THANK YOU.
THE PREMISE OF THIS CONCEPT
PROPOSAL WAS THAT THE EXPOSOM
PLAYED A SIGNIFICANT ROLE IN
AGE RELATED DISEASES AND THE
CHARACTERIZED EXPOSOME
REQUIRES BOTH MENTAL AND
BIOLOGICAL SAMPLES SO THE GOAL
HERE IS TO CREATE TECHNOLOGY
THAT COULD BE USED BY
CAREGIVERS AND SUBJECTS
THEMSELVES IN ANY SITUATION OR
LOCATION SO THAT WOULD THEREBY
ALLOW A WIDE AND DIVERSE RANGE
OF SUBJECTS AND CAREGIVERS
THAT PREVIOUSLY HAD NOT BEEN
ABLE TO PARTICIPATE IN THESE
TYPE OF EXPOSOME STUDIES TO
BETTER PARTICIPATE AND THEN TO
THEREFORE CAPTURE A WIDER
RANGE OF PARTICIPANTS
CHARACTERIZATION IN THE
EXPOSOME.
SO THAT WILL ADDRESS AT LEAST
THREE FUNDAMENTAL GOALS OF THE
NIA AND CREATING STUDIES TO BE
USED BY CAREGIVERS THAT WOULD
BE A NEW APPROACH.
AND SO WE SAW, I THINK,
SUPPORTS FOR THIS CONCEPT.
>>THANK YOU, Dr. LONGO.
DOCTOR REUBEN, YOU HAVE
ANYTHING TO ADD?
>>NO, I WOULD JUST SAY I
SUPPORT AND THE SHORT TERM WAS
ABOUT THE TECHNOLOGY AND
LONG-TERM GOAL WAS ABOUT THE
OPTIONS TO HELP UNDER
RESOURCED POPULATIONS.
>>SO OVERALL THERE WAS
GENERAL ENTHUSIASM FOR THE
CONCEPT AND THE COUNCIL AGREED
TO MOVE FORWARD AND VOTED TO
MOVE FORWARD WITH THE CONCEPT.
THE SECOND THING WE WOULD LIKE
TO DISCUSS IS THE ROLL F ROLL
F REPORT FOR THE DEA/OSEP
PROCESS AND I THINK Dr.
KIZOWSKY IS ON THE LINE TO
TALK ABOUT THAT.
>>YES, I AM HERE, LET ME
SHARE MY SCREEN WITH YOU.
YES, THANK YOU.
IF THERE IS SOME PROBLEM WITH
THE VIDEO LET ME KNOW.
-- KRITCHEVSKY.
THIS GROUP WAS ENPANELLED LATE
LAST YEAR, THE COMMITTEE
ROSTERS HERE, MOSTLY CURRENT
AND FORMER COUNCIL MEMBERS BUT
SOME OTHER NOTABLE LINES ALSO
PARTICIPATED.
WE WERE ASKED TO REVIEW THE
OVERALL RESEARCH GOALS AND
PROVIDE SUGGESTIONS ON
DIRECTIONS AND EVERYONE SEIZE
GOING FORWARD.
THE GOALS ARE LIFTED HERE,
OVERALL GOALS, CONTRACT RAISE
FACTORS IN OLDER PERSONS THAT
INFLUENCE RISK AND SEVERITY OF
MORBIDITIES, DISABILITIES,
SYMPTOMS, VULNERABILITY TO
STRESSORS, THIS IS THE PURVIEW
OF THE GERIATRICS BRANCH.
THE CLINICAL GERONTOLOGY
BRANCH LOOKS AT CHARACTERIZE
FACTORS THAT INFLUENCE CHANGES
OVER THE LIFESPAN AFFECTING
HEALTH SPAN AND LONGEVITY AND
THE CLINICAL TRIALS BRANCH
LOOKS AT DEVELOPING AND
TESTING INTERVENTIONS TO TREAT
OR PREVENT AGE-RELATED
CONDITIONS AND EXTEND HEALTHY
LIFESPAN.
THE GROUP WAS ALSO ASKED TO
IMPROVE PIPELINES FOR
DEVELOPING NEW INTERVENTIONS
THAT MERIT TESTING IN CLINICAL
TRIALS AND TO ACHIEVE
SUFFICIENT RESEARCH POPULATION
DIVERSITY TO ADDRESS CAUSES
AND EFFECTS OF
DIVERSITY-RELATED FACTORS AND
ON ITS OWN THE COMMITTEE CHOSE
TO ALSO INCLUDE WORKFORCE
DIVERSITY BECAUSE IT
INTERSECTS WITH MANY THINGS WE
HAVE JUST HEARD AND THE
COMMITTEE WANTED TO DISCUSS IT
FURTHER.
THIS IS A SCHEMATIC OF HOW THE
DIVISION THEN ALLOCATES ITS
RESOURCES.
OF I WOULD MOSTLY POINT AT THE
AWARDS, UPPER RIGHT, MOST OF
THE AWARDS ARE IN THE
GERIATRICS BRANCH IN
GERONTOLOGY AND CLINICAL
TRIALS, REFLECTS WHERE THE
NEED IS BUT ALSO THE KINDS OF
GRANTS COMING IN.
ABOUT 9 PERCENT OF THE BUDGET
GOES TO THE TRAINING AND YOU
CAN SEE ABOUT HALF MILLION
DOLLARS IN DIVERSITY
SUPPLEMENTS.
SO A FEW INITIAL REMARKS, I
WANTED TO JUST CONGRATULATE
THE DIVISION ON THEIR LAST
REVIEW, I THINK IT WAS SEVERAL
YEARS AGO, TO LIMIT THE AMOUNT
OF WORK DONE OVER THAT
INTERVAL, TREMENDOUS
ACHIEVEMENT, AND ALSO WANTED
TO JUST THANK THE DIVISION
LEADERS, THE BRANCH CHIEF
HADLEY AND OTHERS BEING
INCREDIBLY HELP HELPFUL.
THE COMMITTEE WAS PROVIDED
WITH VERY PERTINENT MATERIALS
THAT CERTAINLY HELPED US IN
OUR JOB.
THE COMMITTEE WAS REALLY
IMPRESSED BOTH BY THE URGENCY
AND SCOPE OF THE MISSION.
THE URGENCY, IF YOU LOOK WHEN
THE PREVIOUS REVIEW WAS
COMPLETED WHICH WAS 2015 TO
SEVEN YEAR PERIOD, TO 2030,
THE OLDER PERSON IN THE --
PERSONS IN THE UNITED STATES
WILL INCREASE 30 PERCENT SO
THE MISSION IS VERY URGENT AND
WE'RE ALSO IMPRESSED BY THE
SCOPE, FULLY TRANSLATIONAL AND
QUITE COMPREHENSIVE AND THAT
IS ALSO A CHALLENGE WE WILL
TALK ABOUT AND I WOULD ALSO
LIKE TO THANK THE OTHER
COMMITTEE MOMENTS, VERY
ENGAGED.
WE HAVE A LARGE NUMBER OF
SUGGESTIONS AND
RECOMMENDATIONS AND I WILL
COVER THE HIGHLIGHTS IN THIS
REVIEW.
SO SOME BROADER STRATEGIC
RECOMMENDATIONS.
THE DIVISION HAS AN UNUSUAL
PLACE TO PROMOTE HEALTH SYSTEM
AND IMPLEMENTATION FOCUS
RESEARCH, I WILL TALK ABOUT
THAT IN A SECOND.
THE NUMBER OF CONCERNS AND
ISSUES AND OPPORTUNITIES IN
THE CLINICAL TRIALS SPACE AND
WE HAVE A SUGGESTION WHICH I
WILL ALSO ELABORATE ON IN THE
DEVELOPMENTA L SECTION OF THE
CLINICAL TRIAL NETWORK.
ONE OF THE THIRD PIPELINES WAS
QUICKLY DEVELOPED ON THE
BIOLOGY OF AGING AND AN
IMPORTANT NEED TO PUT THOSE
INSIGHTS TO WORK IN A
TRANSLATIONAL WAY.
AND WE ALSO ARE VERY COGNIZANT
OF THE PROBLEMS OF HEALTH
DISPARITIES AND AGING AND
REALLY UNDERSTAND THAT YOU
CAN'T REALLY MAKE ANY
ADVANCEMENT IN THOSE AREAS
UNTIL YOU ALSO INCLUDE IN YOUR
THEORETICAL AND CENTRAL MODELS
SOCIAL DETERMINANCES AND
STRUCTURAL DETERMINANTS.
AND FINALLY GIVEN THIS VERY
BROAD MISSION, COLLABORATIONS
ARE CRITICAL AND WITH THE
OTHER DIVISIONS WITHIN NIA,
PHARMA, PCORI, FDA AND OTHER
ICS.
THE MISSION IS BROAD ENOUGH
THAT NO AMOUNT OF MONEY, IT IS
ALMOST INEXHAUSTIBLE RESOURCES
SO THE WAY TO MAKE
ACHIEVEMENTS FOR ADVANCES ARE
IN ALLIANCE AND PROVIDING
CATALYTIC SUPPORT IN
COMBINATION WITH OTHER
PARTNERS AND STAKEHOLDERS.
WITH THAT SAID, LOOKED AT EACH
BRANCH.
THE MAJOR RECOMMENDATION FOR
THE GERIATRICS BRINGCH WAS TO
CONSIDER TWO SUBBRANCHES,
WHETHER STRUCTURAL OR
CONCEPTUALLY, ONE FOCUSING ON
BASIC, CLINICAL AND
TRANSLATIONAL RES
A LARGE AMOUNT OF GERIATRIC
WORKFORCE IS ACTUALLY
INTERESTED OR DEVOTING THEIR
TRAINING TO ITEM 2 WHICH IS
HEALTHCARE RESEARCH WHICH
FOCUSES ON DIAGNOSTICS,
PROPRIATE USESEF
INTERVENTION, INNOVATION AND
CARE CENTERS ANDUSING
ON CARE DELIVERED AT SITES
WHERE OLDER PERSONS LIVE OR
RECEIVE CARE.
IT IS INCREASINGLY IMPORTANT
AT NIH IN A RESOURCE STARVED
ENVIRONMENT TO DID BETTER JOBS
DELIVERING CARE AND THIS IS
VERY IMPORTANT FOR OUR
MISSION.
WE ENCOURAGE THE DIVISION WORK
CLOSELY WITH THE DIVISION OF
NEUROLOGY, INCREASE SUPPORT
FOR WORKING IN MEDICAL
MANAGEMENT FOR THOSE WITH ADRD
AND ONE OF THE PROGRAMS, THIS
BRANCH OVERSEAS IS THE PEPPER
PROGRAM.
THE COMMITTEE WAS VERY LAUD
TORE ON THIS AND GIVEN THE
URGE DEPENDS SEE OF WHAT CAN
BE DONE TO INCREASE THE NUMBER
OF CENTERS AND FUNDING PER
CENTER.
FOR THE CLINICAL GENUINE TOLGS
BRANCH, THE COMMUNITY REALLY
EMPHASIZED THE IMPORTANCE OF
LONGITUDINAL STUDIES, STUDIES
OF PEOPLE AIFFERENT AGES, A
LOT OF STUDY HAS BEEN DONE TO
MAKE ADVANCESKETHIS AREA.
WITHIN THE NIH, THERE ARE
ONGOING STUDIES, MANY
INITIATED BY OTHER INSTITUTES,
A COMMITTEE THOUGHT A
STRATEGIC REVIEW OF THAT
SUPP IF THERE IS
AVERAGE DIVERSITY ACROSS THE
LIFE COURSE, AND NEW ASSAYS
AND STUDY DESIGNS OR
ANALYTICAL METHODS SHOULD BE
CONSIDERED TO SEE IF NEW
STUDIES SHOULD BE STARTED UP
TO ENSURE THERE IS ADEQUATE
COVERAGE ACROSS ALL THE AREAS
THAT WOULD BE PERTINENT.
THIS DIVISION WORK SHOWS THAT
SCALE IS VERY IMPORTANT.
THE SIGNALS TEND TO BE VERY
FAINT AND SOME PARTNERSHIPS OR
COORDINATION ARE NECESSARY TO
ACHIEVE IT BECAUSE THEY MAY
NOT HAVE THE RESOURCES TO DO
IT ON THEIR OWN.
COMMITTEE VERY INTERESTED INN S
TARGETING THE BIOLOGY OF
AGING.
NEED TO SUPPORT PHASE 2 AND 3
TRIALS AND WE'LL TALK ABOUT
THE NETWORK IN A BIT.
OPPORTUNITIES FOR A LOT OF
PRECOMPETITIVE PROGRAMS WITH
PHARMA.
S A LOT OF WORK IN
PHARMA IN THE BIOMARKER SPACE
THAT COULD BE VERY HELPFUL TO
OTHER INVESTIGATORS AND ALSO
IMPORTANT TO PARTNER WITH NIA
AND NIH TO JOINTLY SUPPORT
RFA'S FOR EARLY DRUG SCREENING
AND ASSAY DEVELOPMENT.
THE BRANCH SUPPORTS THE
BIOBANK, A RELATIVELY NEW
RESOURCE, THE NIH COLLECTED
STUDIES AND SPECIMENS TO BE
DEPOSITED IN A BIOBANK TO
ALLOW OTHER PEOPLE TO USE THAT
IN THEIR DISCOVERY SCIENCE OR
AS A SOURCE OF SAMPLES FOR
THEIR RESEARCH IS VERY
PROMISING AND ENCOURAGE
DEVELOPMENT.
CURRENTLY MORE SOCIALIZATION
TO THE WORLD THAN WHAT IT IS
NOW AND HOW IT MIGHT BE USED
IS RECOMMENDED AND AS PEOPLE
THINK ABOUT IT, WILL BE A VERY
WELL USED RESOURCE.
SPECIFIC AREAS WARRANTING
ATTENTION AND I WANT TO
EMPHASIZE THESE THINGS THAT I
AM SAYING AREN'T JUST THAT THE
DIVISION DOESN'T DO THEM BUT
THAT THESE ARE -- AND WITH ALL
THE THINGS I AM SAYING BUT IT
JUST SEEM OF PARTICULAR
SALIENT -- SEEM PARTICULARLY
SALIENT TO THE COMMUNITY.
A LOT OF WORK IN OBESITY IN
ADULTS AND ITS TREATMENT AND
BEYOND FOOD IN AND FOOD OUT
DIETARY PATTERNS.
THE EPIDEMIOLOGY AND DIETARY
PATTERNS ARE IMPORTANT FOR
HEALTH OUTCOME AND PERSISTENT
AND THE IMPORTANCE OF FOLLOW
UP WITH THAT.
A LOT OF USING IPSC'S AND
LAB-ON-A-CHIP TECHNOLOGY TO
EXPLORE AGING SYSTEM AND
BIOLOGY AT THAT LEVEL AND
AGAIN, THE RESOURCE ABOUT
BIOMARKERS, THESE ARE TWO
AREAS THE TWIGS COULD WORK
WELL WITH THE DIVISION -- THE
DIVISION COULD WORK WELL WITH
THE DIVISION TO EXPLORE.
AND THERE IS AN OPPORTUNITY TO
HAVE MORE IMPORTANCE ON THE
IMMUNE SYSTEM FROM THREE
VARIOUS ASPECTS.
ONE IS AGING PER SE AND IN A
TRANSLATIONAL WORLD, SERVES AN
IMPORTANT ROLE ON ORGANISMAL
AGING AND AS A RESPONSE TARGET
TO INTERVENTION AS WELL.
SO A LOT OF OPPORTUNITIES TO
INCREASE THE SCIENCE IN THAT
AREA.
SO IN TALKING ABOUT THE
CLINICAL TRIALS BRANCH, WE
REALLY FOCUSED ON IMPROVING
THE PIPELINE FOR DEVELOPING
NEW INTERVENTIONS BECAUSE WE
SORT OF INCORPORATED A LOT OF
THE MISSION OF THE BRANCH IN
THIS ONE REQUEST.
WE THOUGHT ABOUT THE POOL OF
INVESTIGATORS AND THE
COMMITTEE IS CONCERNED THAT
THE POOL IS SMALL AND LACKS
DIVERSITY AND EXPERTISE.
IF YOU LOOK AT ALL OF THE
PEOPLE WITH DECENT AWARDS THAT
THE NIH CURRENTLY FUNDS, VERY,
VERY FEW OF THEM ARE DOING
ANYTHING THAT IS RELEVANT TO
THIS AREA.
THERE IS ALSO MOTIVATION TO
DEVELOP TRIALS AND DECIDING
WHICH INTERVENTIONS, MERIT
TESTING IS A GREAT AREA FOR
COLLABORATION ACROSS THE
INSTITUTE AND WITH PHARMA AND
CMS.
SO WE SUGGEST DEVELOPING A
CLINICAL TRIAL PLATFORM WITH A
COORDINATING CENTER AND
AFFILIATED CENTER AND WANTED
TO MOSTLY POINT OUT THE
BENEFITS OF THIS OR EFFICIENCY
GAINS BECAUSE THERE ARE FIXED
COSTS IN ADMINISTRATION THAT
COULD BE SPREAD ACROSS TRIALS,
HAVING RFAS COULD EFFICIENTLY
ADDRESS DIVISION PRIORITIES.
RECOMMENDATIONS HAVE TO DO
WITH OVERSIGHT MODELS THAT
MIGHT BE EXAMINED IN OTHER
INSTITUTES THAT ARE PHASEDSE
PROVIDE SOME CONTROL AND
ABILITY TO DIVERT -- TO FOCUS
RESOURCES ON SUCCESSFUL TRIALS
AND PROMOTE INTERVENTIONS WITH
SPECIAL RELEVANCE.
THESE ARE MULTIMODAL
INTERVENTIONS WITH MULTIMODAL
INTERVENTIONSAND PROMOTING
PHARMACOTHERAPIES.
NOW I ACTUALLY DON'T NEED TO
SAY MUCH ABOUT THIS BECAUSE I
THOUGHT THE SECTION THAT CAME
FROM THE WORKING GROUP PRIOR
TO THIS MADE THESE POINTS ALL
VERY WELL SO I WANT TO
EMPHASIZE OUR COMMITTEE SAW
THIS ALL THE SAME WAY AND
AGREE THAT RESOURCES ARE
NEEDED TO BUILD THOSE TRUST
RELATIONSHIPS.
WITH RESPECT TO WORKFORCE,
PRETTY COMPREHENSIVE AND OUR
COMMITTEE AGREES WITH THEM BUT
THESE ARE STRATEGIES FOR
WORKING WITH PEOPLE EARLIER IN
THEIR CAREERS TO BRING
INTEREST TO AGING AND YOU CAN
READ FOR YOURSELF SOME OF
THESE STRATEGIES.
SO OUR WRITTEN REPORT IS IN
THE PENTULTIMATE VERSION.
WE WILL PRESENT THE FINAL
REPORT, I HOPE, TO Dr. HODES
ON MAY 31ST.
TH
.
>>STEVE, THANK YOU SO MUCH FO.
WE HAD -- AND WE REALLY
APPRECIATE THE TREMENDOUS
AMOUNT OF WORK THAT YOU AND
OTHER MEMBERS OF THE COMMITTEE
DID ON THIS REPORT.
WE HAD A VERY LIVELY AND
INSIGHTFUL DISCUSSION ABOUT
THIS YESTERDAY AND ARE LOOKING
FORWARD TO THE FINAL REPORT.
JUST WANT TO ASK IF THERE ARE
ANY OTHER THOUGHTS OR
QUESTIONS THAT THE
COMMITTEE -- THAT COUNCIL MAY
HAVE BEFORE WE CLOSE THIS
PART?
OKAY, SO IF NOT, THE FINAL
THING THAT THE WORKING GROUP
DISCUSSED WAS CFR'S
INITIATIVES TO STRENGTHEN PEER
REVIEW WITH Dr.S SPAN AND
YOU WANT TO SUMMARIZE THAT
CONVERSATION?
>>YES, SO WE HAD Dr. SPAN
GIVE US A TALK ON
STRENGTHENING PEER REVIEW.
SHE IS THE DIRECTOR OF THE
DIVISION OF NOURISH SCIENCE
AND AGING SCIENTIFIC REVIEW
AND IN HER PRESENTATION, SHE
FIRST STARTED OFF WITH GIVING
US SOME STATISTICS OF THE
SCOPE OF APPLICATIONS REVIEWED
AT CSR, DETAILING THAT THE NIH
RECEIVED APPROXIMATELY 79,000
APPLICATIONS EACH YEAR AND
THAT THE CSR REVIEWS
APPROXIMATELY 60,000 WHICH IS
76 PERCENT OF THOSE
APPLICATIONS.
THEY HAVE A STAFF OF 2775 SROS
WHICH LEAD TO 19,000 -- SORRY,
1200 MEETINGS PER YEAR
UTILIZING 19,000 REVIEWERS.
SO IN THE PRESENTATION, SHE
TALKED ABOUT FIVE DIFFERENT
WAYS IN WHICH THEY ARE TRYING
TO STEPBGTEN PEER REVIEW HERE
AT THE NIH.
THE FIRST POINT SHE MADE WAS
ABOUT THE EVALUATION PROCESS
THAT GOES ON IN CSR.
THIS PROCESS IS CALLED INQUIRE
WHICH STANDS FOR EVALUATING
PANEL QUALITY AND REVIEW.
THIS PANEL, IT DOES
APPROXIMATELY 20 PERCENT OF
THE DIFFERENT INITIATIVES EACH
YEAR THAT -- I'M SORRY, THE
STUDY SESSIONS THAT OCCUR IN
CSR EACH YEAR TO
APPROXIMATELY -- AND THEY
GROUP THESE ACCORDING TO
SCIENCE AREAS.
THIS PANEL DOES A THOROUGH
REVIEW AND IT GOES THROUGH
SEVERAL PROCESSES OF AAPPROVAL
AND PRESENTATION AT THEIR
COUNCIL TO GET THE GROUP OTHER
CHANGES OR RECOMMENDATIONS FOR
EACH OF THOSE STUDY SECTIONS.
SO APPROXIMATELY EVERY FOUR TO
FIVE YEARS, EVERY SECTION OR
CSR DOES GET REVIEWED.
NEXT THEY HAVE TALKED ABOUT
THE SIMPLIFYING THE PEER
REVIEW PROCESS.
IN THIS PRESENTATION, SHE
DISCUSSED THE HEALTH.
THEY ARE GOING TO BE CHANGING
THE REVIEW CRITERIA AND OUR
FUNDING OPPORTUNITY.
AS FETCH KNOWS RIGHT NOW THERE
ARE FIVE MAJOR REVIEW CRITERIA
SIGNIFICANT INNOVATION,
INVESTIGATORS APPROACH AND
ENVIRONMENT, SO RIGHT NOW THEY
ARE PROPOSING TO CHANGE THAT
INTO THREE DIFFERENT CRITERIA,
FIRST BEING IMPORTANCE OF THE
RESEARCH WHICH WOULD ENCOMPASS
SIGNIFICANCE IN INNOVATION.
SECOND BEING RIGOR AND
FEASIBILITY WHICH IS REALLY
THE APPROACH AND THEN FINALLY
EXPERTISE AND RESOURCES WHICH
WAS CURRENTLY THE INVESTIGATOR
ENVIRONMENT.
BUT THIS LAST ONE WILL NOT GET
A SECOND SCORE.
LIKE JUST GET INCORPORATED
INTO THE OVERALL FINAL IMPACT
SCORE FOR THE APPLICATION
ITSELF.
NEXT THEY DISCUSSED THE N NSRA
FELLOWSHIP.
THROUGH THEIR ANALYSIS THEY
DISCOVERED MOST OF THE
FELLOWSHIPS FELL WITHIN A VERY
SMALL SUBSET OF INSTITUTIONS
SO THEY WERE LOOKING TO
ADDRESS THIS SITUATION AND
HOPE TO REVISE THE
APPLICATIONS PROCESS AND THE
REVIEW CRITERIA OF THE FELLOW
SHIPS THEMSELVES.
NEXT THEY TALKED ABOUT
FAIRNESS IN REVIEW SO THEY --
CSR HAS INSTITUTED TWO
TRAINING INITIATIVES FOR OUR
REVIEWER.
FIRST BEING BIAS AWARENESS.
THEY HAVE ALREADY HAD ABOUT
20,000 OF OUR REVIEWERS TAKE
THIS COURSE ALREADY AND IT HAS
BEEN WELL RECEIVED.
THE SECOND TRAINING MODULE
THAT THEY ARE INSTITUTING IS
ON INTEGRITY ALSO SO -- AND IT
IS BASED ON ACTUAL CASES THAT
HAVE BEEN PRESENTED TO THE
NIH.
AND SO THAT ALSO IS BEING
INCORPORATED INTO THE TRAINING
OF OUR REVIEW PANEL MEMBERS
AND THIS IS GOING TO BE
ENACTED BY MAY OF 2024.
FINALLY THEY ALSO TALKED ABOUT
DIVERSITY IN THE REVIEW PANEL
AND THEY GAVE US SOME
STATISTICS ABOUT HOW WE WOULD
INCREASE DIVERSITY IN OUR
PANEL.
WE ARE NOW IN THE PAST YEAR --
THERE WAS -- WITH REGARDS TO
SENDER, 45 PERCENT OF THE
REVIEWERS ARE WOMEN AND
18 PERCENT ARE IN THE
UNDERREPRESENTED MINORITY
CATEGORY.
SO THERE ARE SEVERAL EFFORTS
BEING TAKEN BY CSR TO INCREASE
DIVERSITY IN OUR PANEL AND
THEY ARE CONTINUING THEIR
EFFORTS IN THIS AREA.
SO THAT'S BASICALLY THE
SUMMARY OF HER PRESENTATION.
>>THANK YOU, KEN.
ARE THERE THERE ANY OTHER
QUESTIONS OR CONCERNS ABOUT
THAT?
OKAY, IF NOT, THEN WE'RE
COMPLETED WITH THE PROGRAM.
>>GREAT, THANK YOU, SUSAN.
JUST A FEW MORE THINGS.
FIRST, I NEED TO CONSIDER THE
MINUTES FOR THE LAST COUNCIL
MEETING.
SO THE MINUTES FROM THE LAST
COUNCIL MEETING WITH POSTED IN
THE ELECTRONIC COUNCIL BOOK
AND I WOULD LIKE TO GET A
MOTION THEN TO APPROVE THE
MEETING FROM THE JANUARY 2023
COUNCIL.
IF I COULD GET A
RECOMMENDATION TO APPROVE?
>>SO MOVED.
>>AND A SECOND?
ALL IN FAVOR?
ANY OPPOSED?
[INAUDIBLE]
>>OH, YEAH, THAT IS OKAY BUT
THE MEETING MINUTES ARE IN FOR
YOUR INFORMATION BUT YOU DON'T
NEED TO VOTE AS A NEW MEMBER
TO THE COUNCIL, YEAH.
THANK YOU FOR THAT.
OKAY, THANK YOU VERY MUCH.
AND THEN JUST FOR FUTURE
MEETING DATES FOR COUNCIL,
JUST AS A REMINDER, OUR NEXT
COUNCIL MEETING IS IN
SEPTEMBER.
IT WILL BE TUESDAY,
SEPTEMBER 19TH AND WEDNESDAY,
SEPTEMBER 20TH.
ALSO HERE IN BUILDING 45,
NATCHER, IN-PERSON SO WE WILL
BE HAVING OUR NEXT MEETING
SEPTEMBER 19TH AND 20TH HERE
AND IN 2024, OUR MEETING
SCHEDULE IS AS YOU SEE UP
HERE, JANUARY 23RD AND 24TH
AND THAT WILL BE A VIRTUAL
NEATING.
WE HAVE DECIDED EARLIER ON
WHEN WE WENT BACK TO BEING
IN-PERSON MEETINGS THAT WE
WOULD HAVE TWO IN-PERSON
MEETINGS EACH YEAR AND ONE
VIRTUAL MEETING WHICH WOULD BE
IN OUR JANUARY -- AND THIS IS
MOSTLY BECAUSE OF THE
UNPREDICTABILITY OF THE
WEATHER SO THAT IS OUR JANUARY
MEETING AND THE MAY COUNCIL
NEXT YEAR IS MAY 22ND AND 21ST
HERE IN BUILDING 45 AND
FINALLY OUR SEPTEMBER COUNCIL
OF 2024 IS ON SEPTEMBER 18TH
AND 19TH AND THAT IS GOING TO
BE IN BUILDING 31.
SO THAT'S ALL FOR YOUR
INFORMATION.
SO AT THIS POINT, WE'RE GOING
TO TAKE A BREAK, A 15-MINUTE
BREAK AND THEN WE'RE GOING TO
COME BACK AND WE HAVE TWO
SPEAKERS FOR COUNCIL.
OUR FIRST SPEAKER IS Dr.
HONG-WEN DENG, TALKING ON
TRANS-OMICS STUDIES OF COMPLEX
AGING DISEASES AND THE NEXT
SPEAKER IS Dr. RICK WOYCHIK
FROM THE NATIONAL INSTITUTE OF
ENVIRONMENTAL HEALTH.
SO WE WILL HAVE THOSE AFTER
THE BREAK.
>>THANK EVERYONE FOR THE
FANTASTIC IN-PERSON MEETING,
APPRECIATE THE EFFORT YOU HAVE
MADE TO BE HERE AND WELCOME
ANY FEEDBACK IN OUR PLANS.
THE TWO OF THREE, PEOPLE
CUTTING BACK A LITTLE BIT ON
TRAVEL TO TAKE ADVANTAGE OF IN
PERSON BUT WELCOME ANY
COMMENTS NOW ABOUT HOW WE HAVE
DONE.
I KNOW FOR MYSELF IT HAS BEEN
EX SIDE OF THING TO SEE
EVERYONE AND HAVE INTERACTION
WITH REAL PERSONS BUT WE WILL
WELCOME YOUR RESPONSE TO OUR
PLAN.
>>I WOULD LIKE TO REITERATE
WHAT RICHARD JUST SAID TOO, IT
HAS BEEN REALLY GREAT TO HAVE
EVERYONE HERE AND SEE EVERYONE
REACT.
IT HAS BEEN MORE ENGAGING IN
OUR CONVERSATION AND JUST TO
SEE PEOPLE AFTER THREE YEARS
OF BEING COOPED UP IN OUR
OFFICES AND LOOKING AT ZOOM
FOR HOURS AND HOURS AND HOURS,
SO THIS HAS BEEN MUCH BETTER,
MUCH MORE PRODUCTIVE, THANK
YOU.
>>ALL RIGHT WE'LL TAKE THE 15
MINUTE BREAK THEN.
>>WE'RE GOING TO GET
STARTED WITH OUR FIRST
PRESENTATION.
JOHN, ARE YOU GOING TO
INTRODUCE OUR FIRST SPEAKER?
YOU COULD COME TO THE
MICROPHONE THEN?
YEAH, THANKS.
>>GOOD AFTERNOON, EVERYBODY,
JOHN WAYNE, DIVISION OF
BIOLOGY, IT IS MY PLEASURE TO
INTRODUCE OUR SPEAKER.
Dr. HONG-WEN DENG IS
PROFESSOR AND CHIEF OF
DIVISION OF BY BIOMEDICAL
INFORMATICS MEDICINE AT
TULANE.
HE HAS A PH.D. IN QUALM TATIVE
GENETICS AND THEN DID A
POST-DOC IN MOLEC ULAR
GENETICS AND AS A BRIEF
BACKGROUND, PIONEERED
APPROACHES IN MULTI-GENOMICS
APPLICATIONS IN DESCRIBING
WHISK FOR OSTEOPOROSIS POSES
AND HAS RECENTLY STARTED
WORKING WITH Dr. MILLER IN
THE DIVISION OF NEUROSCIENCE
AND LEVERAGING HIS LARGE
DIVERSE COHORT FOR AD AS WELL.
AND I AM LOOKING VERY MUCH
FORWARD TO HEARING HIS TALK.
I AM HONG-WE N DENG, DIVISION
CHIEF AND DIRECTOR.
THANK YOU SO MUCH FOR BEING
HERE, DEEPLY HUMBLED BY YOUR
PRESENTATION.
OSTEOPORES, WE CALL IT A LOST
STUDY AND THE PURPOSE OF THE
STUDY IS WE JUST DON'T LOSE
OUR FISCAL AND MENTAL AFFINITY
WHICH WE COULD LAST LONGER
DURING THE AGING.
AS YOU KNOW, THE ULTIMATE
OUTCOME, CLINICAL OUTCOME OF
DISEASE IS TERMED BY MANY
FACTORS.
THE MULTI-OMICS NETWORKS FOR
DISEASE INCLUDING MANY FACTORS
OF SOCIOAND ECONOMYING HEALTH
AND IN THE PAST MOST OF OUR
EFFORTS HAVE BEEN FOCUSED ON
INDIVIDUAL HEALTH, OMICS
STUDIES UNCOVERED A LARGE
NUMBER OF NOVEL LO CI FOR
HUMAN COMPLEX DISEASES.
THIS PROVIDES USEFUL
INFORMATION AND PUSHED THE
FIELD A LOT FORWARD.
HOWEVER AND WE SEE A LOT OF
SIMILARITIES IN OSTEOPORES AND
OTHER FIELDS AS WELL.
HOWEVER THE SPECIFIC
FUNCTIONAL GENOMICS VARIANTS
AND CAUSAL GENES ARE LARGELY
UNKNOWN.
THE GENERAL HYPOTHESIS THAT
INTEGRATIVE TRANS-OMICS
ANALYSIS OF MULTI-OMICS DATA
WILL BE MUCH MORE PRODUCTIVE
AND POWERFUL NOT ONLY
IDENTIFYING RISK BUT ALSO
IMPORTANT ILLUMINATING
FUNCTIONS IN VIVO IN HUMANS.
THIS IS A NIH AND LOCAL
SUPPORTED OMICS STUDY.
I AM VERY GRATEFUL FOR OUR
OFFICERS AND THE GRANTS
HELPING ME DO THIS RESEARCH
WITH A LOT OF HOURS SO THANK
YOU FOR YOUR HARD WORK.
AND WE HAVE AN INTERESTING
GROUP USING NOT ONLY
TECHNOLOGY, WE ALSO DEVELOP
METHODOLOGY BY GRANTS FROM THE
INSTITUTE IN GENETICS AND
QUANTUM GENETICS.
DURING THE YEAR WE HAVE
DETERMINED A COHORT WITH THE
OMAHA OSTEOPORES STUDY WITH
OVER 4000 PATIENTS AND OVER
3250 SUCKED FROM 800 NUCLEAR
FAMILIES.
AND ALSO THE KANSAS CITY
OSTEOPOROSIS STUDY WITH OVER
5000 SUBJECTS.
AND THEN LOST, I MOVED TO
LOUISIANA AS YO POSES, A
DIFFERENT COHORT OF CURRENTLY
OVER 17,000 AND WE HAVE
MULTIPLE PROJECTS FOR
MEASURING BONE, BODY MASS,
LEAN MASS.
THERE ARE DIVERSE DATA THROUGH
YES NARROWS ASKING FOR SO MANY
DETERMINANTS OF HEALTH AND
OTHER SUBJECTS AND SOME OF
THESE SUBJECTS WERE ALSO AS
SAID FOR COVID-19.
SO THIS IS THE DATA WE HAVE
CURRENTLY AND YOU CAN SEE THAT
UNITING THE DATA FROM THE
STUDIES, IT INCLUDES DIFFERENT
ETHNICITIES.
MANY CAUCASIANS AND
AFRICAN-AMERICANS, SOME ASIAN,
HISPANIC AND OTHERS,
INDIGENOUS, INDIANS AND
PACIFIC ISLANDERS AND THE MOST
SUBSTANTIAL DATA WE FOUND IS
HERE AND THEN THROUGH THE LOST
STUDY, THE JUNE 19TH STUDY.
THIS IS ALL CURRENTLY AND
STILL EXPANDING.
OUR MULTI-OMICS DATA WILL
FOCUS ON THE CELLS, THE
OSTEOCLATOGENIC CELLS THAT WE
SEE IN OSTEOPOROSIS.
THIS IS OUR RECENT
COMPUTATIONS FOR THE
MULTI-OMICS STUDY AND I WANT
TO HIGHLIGHT TWO STUDIES.
ONE IS THE DATA FOR
IDENTIFYING OSTEOPOROSIS
BIOMARKERS AND BIOLOGICAL
INTERACTION AND CAUSAL
MECHANISMS.
AND WE KNOW OSTEOPOROSIS
ESPECIALLY IN WOMEN AROUND THE
AGE OF 50 THEY EXPERIENCE LOSS
OF BONE MASS AND INCREASED
SUSCEPTIBILITY TO OSTEOPOROTIC
FRACTURE.
SO IN THIS STUDY WE SEE A HIGH
AND A LOW IN THE RANGE AND
VERY IMPORTANT FOR THESE
GROUPS.
FOR THE OMICS SIDE, WE
CHARACTERIZED THE GENOME AND
WE THEN WE INTEGRATED THE
CELLS TO MONITOR GROUPS OF
MARKERS THAT INTERACT AND THEN
LOOK AT THAT IN GENERAL FOR
THE PROTEIN NETWORK AND ALSO
USED THE MENDELIAN
RANDOMIZATION TO EXPRESS THE
CAUSAL SOURCES FOR BMD.
SO THIS IS THE SPECIFIC
CORPATION WE USED FOR THIS AND
AS FAR AS METHODS, USED VERY
FEW ASSUMPTIONS AND REVIEW THE
MAGNITUDE OF PATIENTS WHO HAVE
OSTEOPOROSIS AND SEE THEY ARE
OVERCOME WITH THIS MENDELIAN
AND WE THIS ACROSS OMICS.
CAPTURING CORRELATION BETWEEN
DIFFERENT OMIC SUBSETS THAT
CAN BE TESTED.
SO WE USE THIS RANDOMIZATION
ANALYSIS TO TEST CAUSAL
EFFECTS FOR SIGNIFICANT
BIOMARKERS AND THIS IS OVER
HALF A MILLION, A VERY BIG
SAMPLE FOR BMD ANALYSIS.
AND WE USE THAT ANALYSIS, WE
IDENTIFY THREE COMPONENTS,
HIGHLY INTERACTIVE GROUPS
ACROSS DIFFERENT OMICS AND
THIS IS THE RESULTS WITH THE
FEATURES AND YOU CAN SEE A LOT
OF INTERACTIONS, CONNECTIONS
ACROSS DIFFERENT OMICS AND
INTERESTING THAT ONE EXAMINER
TO HIGHLIGHT, THIS EX
SUPPRESSION OF HAUS2 WITH
POSITIVE CORRELATION WITH
METHYLATION AND ALSO
METABOLITE THEONINE AND THAT
SEEMS TO IMPLY THE STRONG
INTERACTION WITH THESE TWO
THINGS AND THIS IS BIO MARKER
FROM OUR OMICS.
INTERESTINGLY THERE IS
SIGNIFICANT INTERACTION
BETWEEN HAUS2 WITH
PROTEIN-PROTEIN INTERACTION
AND THERE'S A LOT OF
CONNECTIONS THAT YOU SEE FROM
THE DATA HERE.
AND WE DID THIS RESEARCH AND
MAPPED THOSE THINGS INTO THE
VERY IMPORTANT RATES KNOWN TO
CAUSE OSTEOPOROSIS BUT MANY OF
THOSE THINGS ARE NORMAL AND
THOSE THAT ARE NOT NORMAL
ALREADY ARE HIGHLIGHTED IN
BOTH PLACE, NORMAL ONES
INTERACT AND ARE CONNECTED
WITH THE NORMAL ONES, THE
NORMAL PATHWAY.
AND THE RANDOMIZATION ANALYSIS
REVEALS THAT THIS WHICH I WILL
HIGHLIGHT HAS A SIGNIFICANT
CAUSE FOR BMD AND THIS STUDY,
THIS PREVIOUS STUDY IDENTIFIED
THE GENE EXPRESSION OF FADS2.
THE PREVIOUS METAANALYSIS HAS
SHOWN VARIANTS IN FADS2 WERE
ASSOCIATED WITH HEEL BMD.
SO THE TRANSO MIC MODELS, WE
TOOK THREE OM ICS AND
IDENTIFIED IN 61 GENES THE
DEGS INTERACTING WITH BMD
VARIATION.
THIS RECONSTRUCTED INTEGRATIVE
NETWORKS REVEALED SUBSTANTIAL
PROPORTION OF THESE BIOMARKERS
NOT ONLY INTERACTED WITH EACH
OTHER BUT ALSO ENRICHED IN
SEVERAL WELL-KNOWN SIGNALING
PATHWAYS OR FUNCTIONAL
ACTIVITIES THAT ARE CRUCIAL
FOR OSTEOBLASTOGENESIS AND
OSTEOCLASTOGENESIS.
WE THEN IN THIS STUDY LOOK AT
GUT MICROBIOTA AND HOW IT
IMPACTED THE BONE VIA
B.VULGATUS AND IT IS CLEAR THE
MULTIBIOME AND IN THIS STUDY
WE TOOK IT A STEP FURTHER.
WE TOP LATE THE STUDY HERE IN
AN INDEPENDENT POPULATION AND
ALSO WE PERFORMED FURTHER
INVIVO FOR THE FINDINGS WE
HAVE.
SO WE DID A REGULAR MICRO
GENOMIC STUDY TO IDENTIFY THE
BACTERIA IN THE FECES SPECIES.
AND WE FIND THERE ARE OTHER
THINGS ASSOCIATED WITH BMD.
THE MULTI-OMIC IDENTIFIED IN
THIS VALERIC ACID AND WE
PERFORMED WITH RANDOMIZATION
AND ACTUALLY THE VULGATUS
CAUSED BY SUGAR, THE VULGATUS
LEVELS.
AND AGAIN WE PERFORMED AN
INDEPENDENT VALIDATION IN
ANOTHER INDEPENDENT COHORT.
SO WE TOOK THIS EVIDENCE, WE
SAY WHY WAS THIS FUNCTIONAL OR
VALECIC AND THEN PERFORMED MY
STUDY THROUGH ORAL GAVAGE
EXPERIMENTS AND WHAT WE FIND
IS WITH THOSE WITH VULGATUS
BACTERIA, THEY ARE NOT AS
FIXED AS THE HEALTHY IN THE
BONE AND THE MINERALIZATION IS
NOT AS GOOD AND THE NUMBER
INCREASES COMPARED WITH
CONTROL.
AND WE ALSO SEE BY THE
ANALYSIS OF THE BIOME, WE
FOUND THIS BACTERIA THAT
PRODUCE VALERIC ACID.
AND FOR THE VA LERIC ACID, WE
ALSO DID SOME EXPERIMENTS AND
SEE THE MICE WITH THE VALERIC
ACID HAS BIGGER BONES AND MORE
MINERALIZATION AND MASS.
AND WE FURTHER PERFORMED HOW
THESE VALERIC ACID WILL
INFLUENCE THE MINERALIZATION
AND IT SHOWS THE VALERIC ACID
CAN DECREASE AND INCREASE THE
OSTEOBLAST ENGAGING IN
MINERALIZATION IN STAINING
CULTURE.
AND THAT WE SUSPECT THAT WE
HAVE A SPECIFIC PATHWAY FOR
THIS LEADING MODELS SO WE
HYPOTHESIZED THE INFLAMMATION
PATHWAY WHICH IS IMPORTANT FOR
THE MINERALIZATION BLOCK, WE
HAVE THREE THINGS IN THE
PROTEINS LIKE AN OF A VERY CAT
DOUGH, P65 AND IL10 IN
CULTURED OSTEOCLAST-LIKE CELLS
AND OSTEOBLAST CELLS AND WE
FIND THE EXPRESSION OF
PRO-INFLAMMATORY CYTOKINE AND
THIS IS INCREASED AND
DECREASED EXPRESSION OF
PRO-INFLAMMATORY CYTOKINE SO
WE PROPOSED SOME STUDY WHERE
VALERIC ACID PRODUCING SPECIES
TO REDUCE VALERIC ACID
PRODUCTION WITHIN THE GUT.
WE ALSO PERFORMED OTHER STUDY
THAT I DON'T HAVE TIME TO TALK
ABOUT BUT I WOULD LIKE TO SAY
THIS.
THIS IS THE JUNIOR FACTOR FOR
INTEGRATION AND AS YOU CAN SEE
IT IS VERY, VERY BRILLIANT
EFFECT.
AND SO WE STARTED LOOKING AT
OSTEOPOROSIS BUT THIS RELATES
TO A LOT OF OTHER RISK LIKE
ALZHEIMER'S MECHANISMS IN
DIVERSE POPULATIONS AND THE
WHOLE EXCHANGE OF MUSCLE MASS
AND MUSCLE LEAN BUT THIS STUDY
FOR ALZHEIMER'S GENETIC RISK
HIGHER IN AFRICAN-AMERICANS SO
WE DID 2.0 STUDY.
THIS WAS 20 YEARS AGO IN LONG
PAPER AND THE REASON WHY IT
LAST MORE, THOSE ARE KIND OF
PUBLISHED AND LIKE TO MENTION
THIS IS AFRICAN AMERICAN
STUDENT AND THIS IS
UNDERGRADUATE STUDENT GOING
THROUGH SCHOOL AND GOING TO DO
RESEARCH SHE SAID IN THE
FUTURE.
SO AND WE ALSO DID
CUTTING-EDGE LIKE DRUG
REPURPOSING AND OMICS USING
OUR OWN DATA WITH PUBLIC DATA
AND WHAT WE ARE TRYING TO
PROPOSE IS WE TRIED TO CONNECT
A COHORT ABOUT 13,000 SUBJECTS
AND TO USE FOR THE WHOLE
GENOME SEQUENCING STUDY, AND
COLLABORATE WITH ADSP-FU.S.
CONSORTIM TO LOOK AT THE DATA
AND LEVERAGE OUR EXISTING U19
PROJECT MULTI-OMICS DATA TO
IMPUTE VARIOUS OMICS,
TRANSCRIPTOME AND METHYLOME OF
PBM AND SERUM METABOLOME AND
LIPIDOME DATA IN THE COMBINED
ADSP COHORTS AND THEN WE CAN
TRANSFORM THE DATA IN THE
ANALYSIS AND IN SINGLE NUCLEI,
TRY TO IDENTIFY WHAT GENES,
WHAT CELL, HOW THEY INTERACT
IN THE SPATIAL CONTACT WITH
HUMANS WITH THE HUMAN BRAIN OR
TISSUE.
SO I WOULD LIKE TO BRING THIS
TO YOUR ATTENTION.
MANY OF YOU ARE EXPERTS AND
KNOW MORE THAN I DO BUT FOR ME
IT IS NEW.
THE PBMS WE STUDY FOR MORE
THAN 20 YEARS FOR OSTEOPOROSIS
TURNED OUT TO PLAY A MAJOR
ROLE AND PBMS INSTATE THE
BRAIN PARENCHYMA TARGETING AB
PLAQUES TO REDUCE PLAQUE LOAD
AND PBMS BEHAVE AS HOUSEKEEPER
WITHIN VAS CHEWER BY
ELIMINATING AB MICRO
AGGREGATES FROM BRAIN MICRO
VASCULATURE IN BLOOD
CIRCUMSTANCE CONSIDERATION.
IN 40 TO 60 PERCENT OF AB
PATIENTS GENERATED IN BRAIN
DIFFUSE IN BLOOD AND BE
CLEARED IN PER RIF REMAINLY IN
PBMS.
ABILITY OF AP UPTAKE BY PBMS
DECREASE WITH AGING AND
FURTHER DECREASE IN AD
PATIENTS AND THIS IS THE
REVIEW INTRODUCING THE STUDY
THE SITES THAT HAVE DIFFERENT
FUNCTIONS AND ONE THING THE
MONO SITES IS MUCH EASIER TO
COPY IN THE CELL, IN THE BRAIN
BECAUSE OF THE BLOOD BRAIN
BARRIER.
SO THIS COULD BE NEW TARGET
CELL FOR AB STUDY.
SO THIS IS THE OVERVIEW OF
RESEARCH PLAN AND WHAT I
INTRODUCED IS NOT NEW.
THE METHOD FROM TEN YEARS
ALSO, THAT BIOINFORMATIC
STRATEGY FOR TRANS-OMICS
IMPUTATION, AND THERE'S OTHER
METHODS FOR IMPUTATION AT
DEEPER OMICS LEVELS.
SO I WOULD LIKE TO BRING THIS
UP AGAIN FOR THE REFERENCE
THAT WE CAN USE FOR IMPUTATION
FOR OMICS AND WE CAN DO THAT
NOT ONLY FOR ALL BUT FOR
ETHNIC IN PARTICULAR AND
ASSURE THE EFFICIENCY OF THE
DATA.
THIS IS THE DATA SET WE
DEVELOPED AND THE PILOT BASES
WE ACCUMULATED SO FAR AND THIS
IS FOR THE PEARSON MODEL AND
ABOUT 60 PERCENT VERY WELL
PREDICTED THIS GENE.
I THINK AMERICANS ARE MORE
THAN 2 PERCENT BUT I DISCUSSED
WITH PEOPLE AND FIGURE
ALTHOUGH WE ADJUST FOR
EXCEPTIONS, THE LOCAL
EXCEPTION MAY AFFECT THE GENE
EXPRESSION AND IMPUTATION SO
WE HOPEFULLY INJECT THE
METHYLATION TO BRING THIS UP
AND WITH THIS PROCESS, HOPE TO
FURTHER IMPROVE.
AND AGAIN, THIS IS FOR MICRO
METHYLATION, WE USE THIS MODEL
BASED ON ORIGINAL COMPUTATION
IN THIS KIND OF AREA AND TO
IMPROVE THE PREDICTION AND
THEN THE DEEPENING, THIS IS
FOR METABOLITES AND LIPIDOMICS
AND A LARGE PROGRAMMER OF
METABOLITES CAN BE PREDICTED
WITH GOOD ACCURACY AND THIS IS
AN EXAMPLE TO USE DEEP
LEARNING AND MODEL PREDICTION
TO IMPUTE FROM GUT META-OMICS,
ALL PRODUCED IN THE GUT AND IN
METABIOME.
AND YOU CAN SEE IN THE GUT
THIS FEATURED DIFFERENT
METAGENOMES AND YOU CAN SEE
THE INCREASED ACCURACY OF THE
PREDICTIONS BUT COMPARED WITH
OUR DEEP LEARNING MODEL, OUR
DEEP LEARNING THAT CAPTURED
THE INTERACTION THAT WE CAN
HAVE FURTHER ACCURACY.
SO WE ARE VERY LUCKY THAT MY
PROGRAM ALLOWS THIS AND ALSO
THE DATA, HELPED TO CONNECT
AND ESTABLISH COLLABORATION
WITH Dr. PERICAK-
>>Eddie Vance: AT UNIVERSITY
OF MIAMI.
AND WE FORTUNATELY GOT THE
PILOT PROJECT FROM THEM FOR
ONE YEAR TO STUDY THE
FEASIBILITY OF STRUCTURE AND
TO GET AFUL FULL YEAR OF
AD/ADRD RESEARCH.
ALTHOUGH WE ANALYZED THE AD
DATA BEFORE, WE DON'T KNOW HOW
THAT MATCHES THE
NEUROPSYCHOLOGICAL FUNCTION OR
OTHER DATA.
SO WE TRAINED OUR COMMUNITY
STAFF AND, NO NOW INVOLVED THE
CHAIR AND NEUROPSYCHOLOGIST
INTO OUR TEAM AND THE GOAL WAS
TO RECRUIT 150
AFRICAN-AMERICANS AGE 65 AND
SO FAR HAVE 110 AND HOPE TO
END THIS SUMMER EARLY AND THIS
WILL HELP US JOIN TO WORK ON
AD/ADRD RESEARCH IN LOST
COHORTS FOCUSED ON MINORITIES.
AS YOU CAN SEE MANY OF THE
OLDER WORKS ARE NOT HERE FROM
MYSELF AND JUST REPRESENT WHAT
A BIG TEAM, HARD-WORKING GROUP
AND ALSO SUPPORTIVE PEOPLE
INCLUDING PEOPLE FROM MY OWN
INSTITUTE AND WE ARE DEEP IN
GRATITUDE TO THOSE PEOPLE.
THANK YOU VERY MUCH.
>>ALL RIGHT, THANK YOU VERY
MUCH, Dr. DENG, A TREMENDOUS
AMOUNT OF RESEARCH YOU ARE
INVOLVED IN AND GREAT TO SEE A
SNAPSHOT OF WHAT IS COMING OUT
OF THAT.
SO TIME FOR A FEW QUESTIONS
FROM OUR COUNCIL.
YES.
>>SO THAT WAS VERY NICE.
ONE THING I IT NOTICE AND I
DON'T KNOW, WE ARE DOING SO
MANY OMICS ALREADY, BUT THE
ONE OMICS ALREADY MENTIONED,
YOU HAVE PLANS TO INCLUDE THAT
IN THE -- [INAUDIBLE] BECAUSE
A LOT OF TIMES THE PROTEIN
LEVELS DON'T FALL IN THE MRNA
LEVELS AND THE PROTEINS ARE IN
THE CELL SO WONDER WHERE YOU
ARE HEADING WITH THAT.
>> GOOD QUESTION.
FORTUNATELY WE ARE FUNDED BY
R01 IN PREVIOUS PROJECT AND BY
DOING THIS FIND IN
SIGNIFICANCE YOU MENTION.
THE COVERAGE AT THAT TIME OVER
1000 AND THERE ARE HALF A
MILLION PROTEINS THAT CAN BE
THERE SO THAT LEADS US TO
TRANS-OMICS BUT WE HAVE
RECRUITED A PROFESSOR IN OUR
DIVISION THAT SPECIALIZES IN
TRANS-OMICS AND HOPING WITH
THE CURRENT ANALYSIS WE WILL
BE ABLE TO DO THAT AND ALSO
INCREASE TO THE SINGLE CELL.
THANK YOU.
>>I HAVE A QUESTION HERE.
SO THANKS FOR THAT
COMPREHENSIVE TALK.
MY QUESTION IS ABOUT YOUR
OSTEOPOROSIS WORK AND THE
REALLY NICE TRANSCRIPTION YOU
GAVE US ON THE STEPS THAT YOU
USED, EXCUSE ME, TO, YOU KNOW,
DO THEM IN RANDOMIZATION WORK.
YOU NEEDED A BIG, BIG SAMPLE
TO USE ONE STEP IN UK BIOBAND
AND PROCEEDED IN ALL OF YOUR
STEPS IN WHITE PEOPLE.
SO I WANTED TO KNOW SORT OF
WHETHER AND HOW YOU WOULD
APPLY THOSE TOOLS TO PEOPLE
WHO ARE HISPANIC AND NONWHITE.
AND THEN YOU HINTED AT IT
LATER ON WITH THE IMPUTATION
PIECE AND HOW LOCAL ANCESTRY
MIGHT HELP YOU SOLVE THE
PROBLEM BUT WANTED TO PLUG
THAT THE REVOCATION WORK HAS
BEEN GOING ON IN ALZHEIMER'S
RESEARCH WORK AS WELL.
SO A LOT OF THINGS THAT YOU
SHOWED US COULD BE APPLIED TO
YOUR NEW AD WORK AS WELL.
>>THANK YOU.
YEAH, WE I REALLY DID HALF BUT
IT IS OUR INTENTION TO APPLY
OR CATCH RESULTS THAT APPLY TO
OTHER ETHNIC GROUPS AND USED
THE IMAGE OF THE CELL SO THAT
IS WHY WE USE THAT TO ENABLE
US TO EXTEND TO OTHER GROUPS
IN THE FUTURE.
BUT YEAH THAT IS A GREAT
QUESTION, THANK YOU.
>>OTHER QUESTIONS?
SANJAY?
>>YES, ONE QUICK QUESTION,
GREAT PROJECT, THANK YOU SO
MUCH.
IN YOUR BIOSTUDY WHERE YOU ARE
RECRUITING, YOU KNOW, ARE YOU
GOING TO COLLECT SOME CRITICAL
DATA ON THERE AS FAR AS THE
BIOMARKER, CELL IMAGING
BECAUSE THAT IS A GREAT
OPPORTUNITY FOR YOU TO
CORRELATE YOUR TRANS-OMICS
DATA WITH EMPIRICAL DATA.
>>THANK YOU FOR THIS VERY
IMPORTANT QUESTION, YES WE DO
AND SORRY I DIDN'T MENTION
THAT.
WE COLLECT SERUM AND PLASMA
AND GOING TO GIVE THAT TO THE
UNIVERSITY OF MIAMI AND THEY
ARE GOING TO DO THE BIOMARKERS
FOR AB AND ALSO FOR
CARDIOVASCULAR DISEASE BECAUSE
CARDIOVASCULAR DISEASE AS YOU
KNOW IS HIGHLY --
[INDISCERNIBLE]
>>ALL RIGHT THANK YOU VERY
MUCH, Dr. DENG, GREAT TALK.
Dr. HODES WILL INTRODUCE OUR
NEXT SPEAKER.
>>THANK YOU, GREAT PLEASURE
TO INTRODUCE OUR GUEST
SPEAKER, RICK WOYCHIK,
DIRECTOR OF NATIONAL INSTITUTE
OF ENVIRONMENTAL HEALTH
SCIENCES.
I HAD THE PLEASURE TO VISIT
THEIR COUNCIL AND Dr.
WOYCHIK ABLE TO SIP KATE.
VIEW ON THE LAKE IS QUITE
NICE, WE HAVE THE OCCASIONAL
PUDDLE HERE BUT NOTHING MUCH
MORE.
WE HAD OUR LUNCH OUT ON THE
VERANDA ON A BEAUTIFUL SPRING
DAY, HERE WE HAVE A BOX LUNCH
BUT IT HAS BEEN A GREAT
PLEASURE TO WORK WITH RICK
OVER THE YEARS IN HIS
CAPACITY.
HE HAS BEEN A GREAT LEADER IN
THE ENVIRONMENTAL EXPOSURE,
TAKING ON A GREAT SIGNIFICANCE
TO ALL OF US AND HE HAS PLAYED
A LEADING ROLE THERE.
IN THE EPISODE OF COVID, HE
HAD BEEN CO-CHAIRING THE RADX
EFFORT WHICH I HAD A
OPPORTUNITY TO PARTICIPATE IN
AS WELL SO ACROSS THE SPECTRUM
OF THE INTELLECTUAL SCIENTIFIC
ACTION AT YOU ARE A LEVEL AND
OF COURSE STAFF HAVE BEEN
EXTRAORDINARY AND A GREAT
PLEASURE TO TALK TODAY ABOUT
THE EXPOSOME IN AGING, HUMAN
HEALTH AND DISEASE.
THAT SORT OF COVERS IT.
RICK?
>>THANKS VERY MUCH
RICHARD FOR THIS INVITE TO BE
HERE AND WHAT I WOULD LIKE TO
DO IS TALK ABOUT SOME OF THE
WORK WE ARE DOING AT NIEHS AND
HOPEFULLY THIS WILL BE AN
ATTEMPT TO BRING MORE
ENVIRONMENTAL INFLUENCES AND
INTEGRATE THEM INTO THE FABRIC
OF THE WORK WE DO AT NIA.
SO HOW DO I ADVANCE HERE?
OKAY, I GUESS I DO.
LET ME START OFF WITH THE
MISSION.
IN THE UPPER LEFT, NI HE HS --
THERE WE ARE, THE MISSION IS
TO DISCOVER HOW THE
ENVIRONMENT AFFECTS PEOPLE IN
ORDER TO PROMOTE HEALTHIER
LIVES AND THE VISION TO
PROVIDE GLOBAL LEADERSHIP FOR
INNOVATIVE RESEARCH THAT
IMPROVES PUBLIC HEALTH BY
PREVENTING DISEASE AND
DISABILITY.
THE MOST IMPORTANT PART OF
THAT IS THE PREVENTION PART SO
THEN WE HOPE TO BE WORKING
WITH ALL OF YOU FOR THE
PREDISPOSING TYPE OF
AGE-RELATED DISEASES THAT
IMPACT HUMAN HEALTH.
THE PLAN HAS THREE DIFFERENT
THEMES.
ON THE LEFT IS THE
ENVIRONMENTAL HEALTH SCIENCES
AND WHAT THAT MEANS IS WE ARE
STUDYING AND DECIPHERING THE
BIOLOGICAL PATHWAYS THAT DRIVE
HUMAN PATHOLOGY AND WE WANT TO
UNDERSTAND HOW DIFFERENT
ELEMENTS OF THE ENVIRONMENT
CAN BE IMPACTING THOSE
NETWORKS.
ON THE RIGHT, WE SEE
DATA-TO-KNOWLEDGE ACTION WHERE
WE HOPE TO TAKE THE
INFORMATION WE HAVE GENERATE
AND PUT IT INTO PRACTICE FOR
THE BENEFIT OF PUBLIC HEALTH
AND THE THIRD THEME,
SCIENTIFIC STEWARDSHIP AND
SUPPORT, THE THIRD TEAM, WE
WANT TO MAKE SURE WE'RE
SHARING THAT WITH OTHER
SCIENTISTS AND COLLABORATING
WITH THE COMMUNITY.
SO THAT IS THE MISSION AND
VISION FOR NOW AND WE WILL
STICK WITH THESE THREE TEAMS
BUT THROUGH THE COMING MONTHS
WE WILL BE UPDATING WITH GOALS
ASK STRATEGIES SO BY THIS TIME
NEXT YEAR, YOU WILL SEE WHAT
OUR NEW STRATEGIC PLAN LOOKS
LIKE.
LET ME START WITH -- DO I
POINT TO THE COMPUTER?
OVER HERE?
THANK YOU.
[LAUGHTER] AT YOU?
>>NO, DON'T POINT AT ME.
[LAUGHTER]
>>THERE WE ARE, GREAT.
SO THIS IS STILL DEVELOPING
BUT I WANT TO BE CLEAR THAT
THERE ARE SCIENTIFIC PRIORITY
AREAS THAT WILL EMERGE AND BE
INTEGRATED INTO OUR NEW
STRATEGIC PLAN AND THAT IS
SHOWN HERE.
THESE ARE ALL KIND OF ENTER
DEPEND DENT WITH EACH OTHER,
WE HAVE CLIMATE CHANGE AND
HEALTH, ENVIRONMENTAL JUSTICE
AND HEALTH DISPARITIES,
COMPUTATIONAL BIOLOGY AND DATA
SCIENCE, THE EXPOSOME, THE
PRECISION ENVIRONMENTAL HEALTH
AND MECHANIC CAN FIFTH TICK
AND TRANSLATIONAL TOXICOLOGY.
I CAN'T TALK ABOUT ALL OF
THESE TODAY BUT THERE IS GREAT
INTEREST IN THE ENVIRONMENTAL
HEALTH AND WILL TELL YOU ABOUT
THE INITIATIVES WE ARE DOING
ON A CLIMATE-WIDE SCALE.
SO LETS START ON THE EXPOS
OME.
THIS SLIDE AT NIEHS REPRESENTS
WHAT IS IN THE ENVIRONMENT
THAT CAN IMPACT OUR HEALTH.
IT IS NOT JUST ABOUT THE AIR,
WATER AND SOIL, WE ALSO HAVE
TO BE CONCERNED ABOUT THE
AGRICULTURAL CHEMICALS AND
PESTICIDES, SYNTHETIC
MATERIALS.
YOU HAVE TO BE CAREFUL ABOUT
THOSE THINGS.
WE ALSO STUDY THE EFFECTS OF
THE DISASTERS AND WILDFIRES
BUT WHAT WE COME TO RECOGNIZE
IS IF WE TRULY WANT TO
UNDERSTAND THE IMPACT OF THE
ENVIRONMENT, IT CAN'T BE BY
LOOKING AT ONE OF THESE THINGS
ALONE.
SO WHAT DOES THIS EMERGE IS
THE CONCEPT OF THE EXPOSOME
AND WAS ORIGINALLY DESCRIBED
BY CHRIS WELLS ABOUT THE
TOTALITY OF EXPOSURE OVER THE
LIFE COURSE SO WE ARE LOOKING
AT THAT HOW THIS PREDISPOSES
HEALTH.
SO IT IS NOT JUST ABOUT
STUDYING PESTICIDES OR AIR
POLLUTION OR A PARTICULAR
PLASTICIZERS, WE HAVE TO BE
DOING ALL THESE THINGS AND
FURTHERMORE IT IS NOT JUST
ABOUT THE CHEMICAL AND
PHYSICAL ELMENTS OF THE
EXPOSOME, WE HAVE TO LOOK AT
THE VARY VALUES SO IF WE'RE
TRULY GOING TO BE LOOKING AT
THE TOTALITY OF COMPOSURE, HOW
DO WE DO THIS?
BECAUSE THIS IS TRULY COMPLEX.
INTEGRATING ACROSS THE ENTIRE
SPECTRUM AND INCLUDING
EXTERNAL AND INTERNAL
EXPOSURES, IT IS NOT EASY.
SO WHAT WE DID LAST SUMMER IS
INVITED Dr. JERRY MILLER ONE
OF OUR GRANTE ES, ACTUALLY ON
THE FACULTY AT COLUMBIA AND HE
HAS BEEN LOOKING AT ECONOMIC
SCIENCE THE PAST DECADE OR SO.
SO HE GAVE A PRESENTATION FOR
THE COUNCIL AND CHALLENGED US
WE NEED TO COME UP WITH AN
OPERATIONAL DEFINITION OF THE
EXPOSOME.
WHAT IS IT AND WHAT DOES IT
MATTER?
HE SAID WE WILL HAVE TO BUILD
TECHNOLOGY TO STUDY THE
EXPOSOME BECAUSE WE CURRENTLY
HAVE THE TOOLS BUT NOT THE
TECHNOLOGY TO TRULY CAPTURE
THE EXPOSOME BUT HE ALSO
ADVOCATED FOR WHAT HE CALLED
THE TAG AUTOMATIC EXPOSOME.
THERE ARE THINGS WE CAN DO
EVEN IN TALKING ABOUT THESE
THINGS WITH EXPERIMENTAL
DESIGN.
SO HE LIKE KENNED THIS TO WHAT
HAS HAPPENED IN THE GENOMIC
COMMUNITY IN THE PAST DECADE.
WHEN GENOMICS STARTED, THEY
LOOKED AT LOOKING AT A GENE IN
TIME AND I CAN REMEMBER
LOOKING AT THE GENE IN A
MICROPHONE AND THOSE WERE
PRETTY PRIMITIVE WITH THE
WHOLE TECHNOLOGY WE HAVE WITH
SEQUENCING A GENOME SO LET'S
START WITH THE PRAGMATIC
REVIEW OF THE EXPOSOME.
NIEHS SPONSORED A SERIES OF
WORKSHOPS LAST SUMMER AND I
HOPE SOME OF YOU WERE PART OF
THESE WORKSHOPS BECAUSE WE
WANT TO DETERMINE WHAT DO WE
MEASURE, WHEN, HOW DO WE
MEASURE, WHAT DO WE MEASURE,
WHAT ARE THE TECHNOLOGIES WE
USE TO TRULY CAPTURE THE
EXPOSOME AND THEN HOW DO WE
SHARE AND TRANSLATE THE DATA
TO HAVE AN IMPACT IN HEALTH
AND DISEASE?
SO THE FINAL REPORTS FROM
THESE WORKSHOPS, DOCUMENTS THE
64 DIFFERENT ISSUES AND IF YOU
ARE INTERESTED, ALL OF THESE
WORKSHOPS WERE RECORDED.
YOU CAN TAKE A LOOK AT THEM,
READ THROUGH THE MINUTES BUT
ONE THING THAT WAS ABUNDANTLY
CLEAR IS WE NEED A
COORDINATION EFFORT.
SO THE CONCEPT OF THE
GLOBALIST RESEARCH AND
COORDINATION WITH ACCELERATING
PRECISION ENVIRONMENTAL HELP
CAME OUT OF THIS.
YOU WILL BE SEEING AN RFA AT
SOME POINT, NOT TOMORROW BUT
OVER THE COURSE OF SEVERAL
MONTHS TO DEVELOP A
COMMONLY-AGREED UPON FRAMEWORK
FOR EXPOSOMICS, PROPOSAL BEST
PRACTICE IN DATA COLLECTION
AND SHARING AND BUILD A GLOBAL
EXPOSOME RESEARCH COMMUNITY OF
DIVERSITY AND INCLUSION TO
FOSTER NATIONAL AND
INTERNATIONAL COLLABORATIONS.
THE FIRST RESEARCH SCOPE IS TO
DEVELOP A COMMONLY-AGREED UPON
CONCEPTUAL FRAMEWORK TO
ADDRESS FUNDAMENTAL QUESTIONS
IN EXPOSOMICS, THEN IDENTIFY
AGREED-UPON TECHNOLOGIES AND
PROMOTE BEST PRACTICE AND
FINALLY BUILD A GLOBAL
EXPOSOME RESEARCH COMMUNITY
AND FOSTER NATIONAL AND
INTERNATIONAL COLLABORATIONS.
NEXT SLIDE.
THE OTHER HAND WE HAVE THIS
GLOBAL EXPOSOME, NEXT SLIDE,
OF IMPLEMENTING EXPOS OME IN
ENVIRONMENTAL HEALTH RESEARCH,
WE DID THIS AT MOUNT SINAI AND
IF YOU ARE A NIH INVESTIGATOR,
YOU CAN SEND YOUR SAMPLES OFF.
IF YOU WANT TO KNOW ABOUT CADM
IUM EXPOSURE, WE CAN DO THAT
BUT MOST IMPORTANTLY THIS IS
THE SUMMER TORE ANALYSIS
LOOKING AT THE TOTALITY OF THE
COMPOSURE.
SO AS I GO ON HERE, WE WANT TO
LOOK AT THE CONCEPT OF
PRECISION ENVIRONMENTAL
HEALTH.
THREE OF OUR GRANTEES GAVE A
PRESENTATION TO OUR COUNCIL
MEETING, ONE FROM BAYLOR WHO
DISCUSSED THIS CONCEPT OF
PRECISION ENVIRONMENTAL HEALTH
AND WHAT THIS IS ALL ABOUT IS
A RESEARCH STRATEGY TO
RECOGNIZE THAT DIFFERENT
PEOPLE RESPOND TO
ENVIRONMENTAL EXPOSURES IN
DIFFERENT WAYS.
SO WHAT MAY BE HARMFUL TO ONE
PERSON MAY NOT BE HARMFUL TO
ANOTHER.
WE HAVE TO FIGURE THIS OUT.
THIS COMPMENTS THE PRECISION
MEDICINE PROGRAM WHERE WE CAN
SEE SEQUENCING FINE HOME IN
VARIATION FOR THERAPEUTIC
INTERVENTIONS OR DIFFERENT
DISEASE OUTCOMES.
BUT THIS IS ALSO ABOUT THE
ENVIRONMENTAL EFFECTS SO WHAT
ARE THE GENES AND EPIGENETIC
CHANGES THAT MAY BE
INTERACTING WITH THE
ENVIRONMENTAL EXPOSOME.
SO THE GOAL HERE IS TO
UNDERSTAND INDIVIDUAL RISK TO
PREVENT DISEASE.
SHARON SEPARATED IT IS VERY
SIMPLE, IT IS GXEXD BUT THE G
PART IS COMPLICATED BECAUSE
THERE IS NO SINGLE AGAIN OR
VARIATION WITHIN A GENE THAT
PREDISPOSES TO AIR POLLUTION.
THESE ARE COMPLEX TRAITS AND
THIS IS JUST LIKE THE GENETICS
OF MOST COMMON DISEASES SO
THERE'S NOT A SINGLE GENE BUT
POTENTIALLY HUNDREDS OF
THOUSANDS OF DIFFERENT GENES
THEREIN THAT WILL COLLABORATE
TO A GENETIC PREDISPOSITION.
SO FOR THIS REASON WE NOW THE
IT WOULD BE GOOD TO MAYBE
COLLABORATE WITH THIS NEW
EMERGING COLLABORATIVE EFFORT
CALLED THE INTERNATIONAL
COMMON DECEMBER ALIGNS.
AND MAYBE SOME OF YOU WERE
WITH ME WHEN FRANCIS COLLINS
LAUNCHED THIS.
AND IN ADDRESSING COMPLEX
TRAITS, WE SHOULD BE WORKING
COLLABORATIVELY TOGETHER SO
THE COHORTS IN ICELAND AND
OTHER PLACES SHOULD BE
SEAMLESSLY INTEGRATED TOGETHER
TO FIGURE OUT WHAT THE HUGE
COHORTS ARE.
SO WE ARE WORKING TOGETHER TO
ELIMINATE THE WAY THE ICD A
AND OTHER LARGE TEN NET TICKS
AND EPIGENETICS CENTERS
COLLECT DATA AND FURTHERMORE,
LET'S DO SOME METHYLATION
CHANGES THAT MAY BE ASSOCIATED
WITH A PHENOTYPE OF DISEASE
INCLUDING EXPOSOMIC AND
EPIGENETICS.
SO WE DID THIS BY REACHING OUT
TO THE ICD A AND MANY OF YOU
KNOW ABOUT THIS, THE ALL OF US
RESEARCH PROGRAM, TO REACH OUT
TO ONE MILLION PEOPLE LIVING
IN THE U.S.
VERY SUPPORTIVE OF THIS NOTION
OF INTEGRATING ENVIRONMENTAL
EXPOSURE INTO THE RESEARCH.
SO THE EMPHASIS IS ON GENOMICS
AND BIOSPECIMENS, HEALTH
RECORDS BUT FORTUNATELY NOW
THEY ARE WORKING WITH US TO
INTEGRATE THAT MISSING PIECE
OF THE PIE WHICH IS THE
ENVIRONMENTAL DATA.
SO IF WE HAVE IN PLACE AND
ACTUALLY RICHARD WAS PART OF
THIS IN THE ALL OF US BRAIN
TRUST LAST WEEK, WE HAVE THREE
PHASES.
THE KWEURS IS TO GET ADDRESS
INFORMATION WHERE SOMEONE
LIVES, WHERE THEY WORK, WHERE
THEY LIVED IN THE PAST AND
INTEGRATE IT INTO THE ALL OF
US PROGRAM.
AND THEN LET'S WILL GO GET
THEIR ZIP CODES BY NUMBER OF
ZIP CODES AND WITH THIS
INFORMATION WE CAN BRING TO
BEAR SOME VERY POWERFUL DATA
SETS TO BEGIN TO UNDERSTAND
INDIVIDUAL EXPOSURE.
NOW PHASE 3 IS SOMETHING I
DON'T HAVE TIME TO TALK ABOUT
BUT THIS IS WHERE THE PROPOSAL
WOULD BE TO GO BEYOND GI S
DATA AND BEGIN TO LOOK AT THE
TOTALITY OF EXPOSURE USING
THINGS LIKE HIGH RESOLUTION
MASSSPECTOGRAPHY.
BUT ANY WAY TO EMPHASIZE HERE
ONCE YOU HAVE THE ADDRESS AND
ZIP CODE INFORMATION, YOU CAN
BRING IN VERY POWERFUL DATA
SETS AROUND AIR QUALITY
MODELS.
YOU CAN GET A PRETTY GOOD SET
OF DATA ON WHAT PEOPLE'S
EXPOSURE IS BASED ON WHERE
THEY LIVE AND WORK.
THERE ARE ALSO DAILY DATABASES
YOU CAN PASS INTO AS WELL AS
THE CDC SOCIAL VULNERABILITY
INDEX.
SO THE FIRST STEP IS TO WORK
WITH THIS DATA AND SEE IF WE
CAN TAKE IT TO PHASE 3 SO
AGAIN, WE ARE GOING TO MAKE
YOUR LIFE A LOT MORE
COMPLICATED -- MY GOAL.
SO LET'S GO ON WITH THE
REMAINING MINUTES I HAVE HERE,
THE ENVIRONMENTAL HEALTH
SCIENCES, WHY AM I HERE AND
WHY IS THERE THIS INTEREST IN
WHAT I AM DOING AND I WANT TO
STEAL ONE OF RICHARD'S SLIDES
THAT YOU SHOWED WHEN HE WAS AT
NIEHS LAST FEBRUARY.
AND I THINK WHAT IS BECOMING
INCREASINGLY CLEAR IS GENETICS
IS VERY IMPORTANT SINCE
GENETICS IS MY TRAINING BUT
THERE ARE ENVIRONMENTAL
EXPOSURES, AIR POLLUTION,
HEAVY METALS THAT CLEARLY ARE
ASSOCIATED WITH THE
DEVELOPMENT OF AD/ADRB AND
THIS IS TRUE PROBABLY FOR A
WHOLE VARIETY OF OTHER HEALTH
ISSUES AND DISEASES.
SO WE NEED TO INTEGRATE IN A
WAY WITH THE WORK THAT IS
BEING DONE AT THE NATIONAL
INCIDENT INSTITUTE OF AGING
AND OTHER PLACES.
BUT THIS IS ALSO GENERALLY
TRUE WHEN WE LOOK AT THE
HALLMARKS OF AGING, THERE IS
INSTABILITY, NUTRITION,
GENETIC ALTERATION, ALL KINDS
OF THINGS, MITOCHONDRIAL
EXPOSURES SO WE NOW ACCEPT
THAT THERE ARE A NUMBER OF
THINGS THAT IMPACT AGING
BIOLOGY.
SO LOOKING AT THE POTENTIAL
TELOMERE LINKED THERE ARE
MOLEC ULAR MARKERS OF STRESS
OR EXPOSURES AND RESILIENCE TO
UNDERSTANDING DISEASE RISK.
I UNDERSTAND THEY HAVE MADE A
LOT OF PROGRESS IN THE MEETING
HELD ABOUT A MONTH AGO AND
REALLY DEVELOPED STANDARD
OPERATING PROCEDURES SO WE CAN
BE MEASURING TE LOMERES AND
SHARE THIS ACROSS THE GLOBE.
BUT ALSO I THINK WE RECOGNIZE
OVER THE LIFESPAN THERE ARE
EPIGENETIC PROGRAMS THAT
DIRECT HOW OUR GENES ARE
ABOUTS DISRUPTED AND WHAT WE
HAVE COME TO RECOGNIZE IS
THERE ARE WINDOWS DURING THIS
LIFESPAN WHERE INDIVIDUALS ARE
SUSCEPTIBLE TO DEVELOPMENTAL
ORIGINS OF BIOEXPOSURE.
ONE OF THESE ITEMS WAS DONE IN
MY OWN LAB, A PESTICIDE NOW
OFF THE MARKET CALLED ROTENONE
AND WE KNOW A LOT ABOUT ITS
ACTIONS, IT SPECIFICALLY
TRANSPORTS THE TRANSCRIPTION
AND REDUCING MITOCHONDRIAL
FUNCTION.
SO WE DECIDE TO TREAT TEN
PARTS DURING PREGNANCY, AT
BIRTH WE STOP THE TREATMENT
AND LOOKED ACROSS THE ENTIRE
METHYLOME OF THE OFFSPRING OF
MOTHERS WITH ROTENONE AND WHAT
WE FOUND IS THESE WOULD BE
METHYLATION SITES ACROSS THE
GENOME, SEE IF I CAN ACTUALLY
DO THIS, AND THERE ARE SOME
SITES WHEN ARE METHYLATED AT
BIRTH, HYPER METHYLATED AND
WHAT WE FOUND IS THERE ARE TEN
PARTS TO A MILLION PARTS OF
ROTENONE DURING PREGNANCY AND
THOSE UP TO 18 MONTHS OF AGE
ARE AFFECTED.
SO LOTS OF THINGS COULD BE
HAPPENING SO THAT WINDOW OF
EXPOSURE DURING PREGNANCY IS
CRITICALLY IMPORTANT.
NOW ONE OF OUR COLLEAGUES DID
SOME STUDIES ON BPA SO IF YOU
ARE DRINKING YOUR SODA OUT OF
A CAN, YOU ARE EXPOSED TO
THIS.
OKAY, I SEE A FEW HANDS BUT
WE'LL TALK AFTERWARDS ABOUT
THIS.
MOST PEOPLE DON'T KNOW YOU ARE
BEING EXPOSED IN A LOOM UP IN
CAN BUT NOT THE PLASTIC
BOTTLE.
SO MOST PEOPLE KNOW ABOUT
THIS.
JUST A FEW DAYS, A RELATIVELY
LOW DOSE OF BPA AND THE BOTTOM
LINE HERE IS WHAT SHE
DETERMINED IS THE EXPOSURE IN
THE NEONATAL PERIOD IS
ACCELERATING AGING AND
METHYLATION AT A NUMBER OF
GENES SO THE NEWBORNS WERE
ACTUALLY LOOKING LIKE ADULTS
AT THEIR MOLECULAR LEVELS.
AND THE RESULTS OF THIS IS
MUCH LATER IN LIFE, INCREASING
THE IMPRESSION OF THIS GENE OF
EGR1 WHICH IS A MASTER
REGULATORY GENE FOR THE
METABOLOME AND WHAT IS
INTERESTING IS SHE FOUND SHE
CAN TRIGGER THE METABOLIC
SYNDROME IN ANIMALS SHE
TREATED WITH BPA WITH A
TYPICAL WESTERN MCDONALD'S
TYPE DIET.
NOW WITHOUT THE DIET, YOU ARE
FINE.
SO I WANT TO EXPRESS MY
APPRECIATION AT NIH FOR THE
COLLABORATIVE WORK WE HAVE
DONE TOGETHER AROUND THE
CONSORTIUM OF TARGET II AND
ENVIRONMENTAL EPIGENOMICS TO
FIND OUT WHAT ARE THOSE
CHANGES INDUCED BY
ENVIRONMENTAL EXPOSURES OVER
THE LIFESPAN AND CAN WE
MITIGATE THESE FACTORS.
SO THIS IS VERY IMPORTANT
RESEARCH AND I THINK I AM AT
20 MINUTES NOW AND I THINK WE
WANTED TO LEAVE TEN MINUTES
FOR Q&A.
SO LET ME JUST GO THROUGH
THESE HERE AND -- JUST GO
TO -- WOOPS, I NEED TO GO BACK
ONE.
SO AGAIN WE HAVE A STRANGE
PARTNERSHIP, BYING INTO THE
EXPOSURE USING EXPOSOME
FRAMEWORK, NOT JUST LOOKING AT
AIR POLLUTION WITH ALZHEIMER'S
BUT ALSO HEAVY METALS IN THE
FRAMEWORK AND ENHANCING OUR
ABILITIES TO LOOK AT THE
BIOMARKERS OF AGING TO MEASURE
THE IMPACT OF THE ENVIRONMENT
AND STUDYING THE GENE
ENVIRONMENT INTERACTIONS TO
UNDERSTAND THE INDIVIDUAL
RESPONSES TO THE ENVIRONMENTAL
EXPOSOME.
SO I WILL STOP AT THAT POINT,
THANK RICHARD AND ALL OF YOU
FOR THE OPPORTUNITY TO BE HERE
AND LOOK FORWARD TO ANY AND
ALL QUESTIONS YOU HAVE.
>>GREAT, THANK YOU SO MUCH,
Dr. WOYCHIK.
WE HAVE TIME FOR QUESTIONS.
>>SURE, THANK YOU.
THE GREAT JUST TO POSITION OF
THE TWO TALKS AND I AM JUST
WONDERING WHAT ARE YOUR
THOUGHTS MOVING FORWARD OF
COMBINING THESE, EXPOSOME
ISSUE AS IT GETS MORE THAT THE
CHEWER AND DEVELOPED AND THEN
THE OTHER APPROACH WE HEARD
ABOUT, IS IT TOO EARLY TO PUT
THESE TWO TOGETHER AND TOO
MASSIVE OR TO WE NEED TO
MATURE A HILL BILL, GET A
BETTER SENSE OF WHAT IS
IMPORTANT AND MERGE THEM IN
PARTICULAR STUDIES --
>>GREAT QUESTION AND MY
SIMPLE ANSWER IS EXPOSOMICS
SHOULD BE ANOTHER TOOL TO
INTEGRATE INTO THE MODELING
TOOL.
SO WE CAN USE THE PRAGMATIC
EXPOSURE AND DO THINGS LIKE
HIGH RESOLUTION AT BEST.
IN FACT, IT IS PRETTY
REMARKABLE WITH THE THINGS YOU
CAN DECIPHER BY LOOKING AT A
MILLILITER OF BLOOD.
THERE ARE OVER 6 O 0
METABOLITES THAT ARE
INDICATORS OF EXPOSURE SO
ADDING THAT TO TRANS-OMICS AND
IN THE END IT WILL BE ALL OF
THESE STRATEGIES THAT MAKE A
TINS.
SO NIEHS, WE HOPE TO BE
LEADING THE STRATEGY TO
DEVELOP THE TYPES OF TOOLS TO
BE DISSEMINATED TO DENG AND
ALL OF YOU SO THAT THIS CAN BE
USED FOR STUDYING THAT GOING
FORWARD.
DID I ANSWER YOUR QUESTION?
>>YES, THINKING OF TOOLS OF
IMPORTANCE, I AM THINKING
ABOUT THE OM ICS STUDIES HAVE
THAT BEEN DONE TODAY, THE ROSS
STUDY, THERE HAVE BEEN STUDIES
DONE AND YOU CAN IMAGINE THOSE
STUDIES ALL OVER AGAIN, YOU
NEED TO BE EXAMINING
EVERYTHING THE SUBJECT IS
EXPOSED TO AND SEEMS LIKE A
PRACTICAL CHALLENGE WHERE YOU
DON'T HAVE TO START OVER AGAIN
BUT THE NEXT TIME YOU LOOK AT
THEM IN A GROUP YOU HAVE THE
EXPOSOME-OM ICS WHERE YOU
DETERMINE THE EXPOSURES.
>>THANK YOU.
A LOT OF OMICS BUT NOT
PROTEOMICS BECAUSE THAT IS
MORE LIMITED AND CHALLENGING.
THE GENERAL QUESTION, YOU KNOW
IS HOW DO WE INTEGRATE ACROSS
ALL THESE DATA SETS AND CROSS
LABORATORIES AND INVESTIGATORS
TO COORDINATE WHAT WHAT IS
BEING DONE TO BE THE MOST
COMPREHENSIVE.
>>I THINK IT IS A GREAT
QUESTION AND PART OF IT IS
JUST BRINGING AWARENESS OF THE
IMPORTANCE OF THE ENVIRONMENT.
REMARKABLY ENOUGH, AND I THINK
THIS GROUP IS PRETTY WELL
INFORMED, BUT THERE ARE A LOT
OF GENETICS AND GENOMICS
GROUPS OUT THERE COLLECTING
BLOOD PRESSURE AND BMI AND
OTHER THINGS THAT -- IN FACT
AT THAT MEETING, THAT KICKOFF
MEETING AND FRANCIS AND ERIC
LAUNCHED, I RAISED MY HAND AND
I SAID WHERE IS THE
ENVIRONMENT IN HERE AND HE
SAID WELL HOW DO YOU STUDY THE
ENVIRONMENT.
THAT WAS HIS RESPONSE.
AND SO THAT IS PART OF WHAT WE
NEED TO DO, INCREASE THE
AWARENESS THAT THERE ARE
ENVIRONMENTAL TOOLS THAT
CONTRIBUTE TO THE DATA AND
THEN PART OF WHAT WE NEED TO
BE DOING IS PACKAGING UP
EXPOSOMICS IN A SEAMLESS WAY
TO BE INTEGRATED SO YOU KNOW
EXACTLY HOW TO USE THIS DATA
TO INTEGRATE IT WITH
TRANSCRIPTOMICS AND
METHYLATION AND OTHER THINGS.
DOES THAT ANSWER YOUR
QUESTION?
>> WE LOOK FORWARD TO WORKING
WITH YOU IN DEVELOPING THAT
INFORMATION.
>>AND APPLYING WHAT WE HAVE
DEVELOPED TOGETHER TO SOME
VERY IMPORTANT DISEASE AREAS
LIKE ALZHEIMER'S DISEASE.
AND EXACT SHE WHAT ARE THE
ROLES OF NOT JUST CADMIUM OR
LEAD OR AIR POLLUTION BUT
REALLY LOOKING ACROSS THESE
DIFFERENT SOURCES AND THEN
LOOKING AT POTENTIAL THE
EPIGENETIC SIGNATURES THAT
ARISE FROM THESE MULTIPLE
EXPOSURES.
BECAUSE IT MAY BE THAT IN THE
END THERE IS A EPIGENETIC
SIGNATURE OF EXPOSURES THAT
COULD BE BEST USED.
WE ALREADY HAVE THE
METHYLATION INTEGRATED IN YOUR
ANALYSIS
>> DOWNSTREAM THE APPLICATION
AND PRACTICE CATS, JUST AS AN
EXAMPLE, WHEN DO YOU TELL
PEOPLE TO TURN IN YOUR
ALUMINUM CANS BECAUSE YOU
DIDN'T KNOW IT WAS THE
ALUMINUM CANS AND NOT THE
PLASTIC BOTTLES THAT MIGHT BE
THE SOURCE OF TOXINS.
-- PRACTICE CATS.
>>WELL, THAT IS COMPLICATED.
THE PFAS, ALL THESE WONDERFUL
THINGS THAT MAKE YOUR CLOTHING
RESISTANT TO WATER, I MEAN
THEY ARE POTENTIALLY DANGEROUS
AND WE JUST HAVE TO BE CAREFUL
WITH THAT.
SO IF YOU WANT TO AVOID THE
EXPOSURE, WHAT ARE THE THINGS
YOU SHOULD STAY AWAY FROM AND
MOST PEOPLE DON'T KNOW THAT
HIGH-TECH DENTAL FLOSS IS
ACTUALLY COATED WITH PFAS AND
IF YOU HOOK AT THE AGREED
KWREPTS OF THESE
PFAS-CONTAINING OR ACTUALLY
THERE WAS AN ARTICLE SOME
PLACE, MAYBE CONSUMER REPORTS,
BUT THE DIFFERENT NONSTICK
PANS AND SO THEY ALL CLAIM
THEY ARE PFFOA FREE.
THAT IS THE ORIGINAL AKOCH BON
TO TEFLON BUT THEY ARE
PROBABLY USING THREE CARBONS
OF PFAS TO REPLACE PFOA SO
THAT IS SOMETHING THAT FALLS
SQUARELY IN OUR DOMAIN AND WE
NEED TO BETTER UNDERSTAND
THAT.
AND IT IS THE ALUMINUM CANS
THAT ARE COATED WITH PLASTICS
THAT KEEP THE COKE FROM
ERODING THE CAN AND THUS THE
BFA.
SO A COMPLICATED QUESTION
THERE, RICHARD, BUT THE OTHER
THING TOO IS IT LOOKING AT THE
MOLECULAR SIGNIFICANTURES OF
EXPOSURE SO WE HAVE TO BE
LOOKING AT EVERY SINGLE
POSSIBLE THING WE'RE EXPOSED
TO THAT WE KNOW AND DON'T KNOW
OR DO WE LOOK AT THE
EPIGENETIC SIGNATURE AFTER A
COMPLEX EXPOSURE AND THAT
MIGHT BE SOME PREDICTION BASED
ON MIGHT HAVE OWN WORK OF AN
AREA THAT I THINK IS AN AREA
WE NEED TO BE EXPLORING MORE.
ANOTHER QUESTION.
>>YES, MAYBE VERY QUICK.
SO I FOUND IT REALLY
INTERESTING THAT YOU ARE GOING
TO BE WORKING ON YOUR
FRAMEWORK FOR EXPOSURE BECAUSE
YOU JUST MENTIONED, AND WE ALL
GROWNED, AND THINKING ABOUT
OUR OWN EXPOSURE FOR THE
VARIOUS PRODUCTS, FOR ME AS A
HEALTH DISPARITY RESEARCHER,
THE ROOT FUNDAMENTAL ROOT OF
ANY FRAMEWORK FOR HEALTH IS
THEISMS.
SO RACISM, SEXISM AND
CAPITALISM.
YOU KNOW PEOPLE ARE SELLING
US -- COMPANIES ARE SELLING US
THESE PRODUCTS THAT ARE
POISONOUS AND THESE ARE FORCES
THAT ARE SORT OF PATTERNING
OUR EXPOSURE TO SOME OF THESE
THINGS BUT ANOTHER QUESTION I
WANTED TO ASK YOU IS YOU
MENTIONED THE GEOCODING IN ALL
OF US AND BECAUSE WE'RE AGING
RESEARCHERS, WE REALLY DO
THINK ABOUT THE ENTIRE LIFE
COURSE.
SO I WANTED TO ASK YOU HOW
THOSE GEOCODED EXPOSURES ARE
AVAILABLE IN PRIOR YEARS.
YOU KNOW GIVEN SOME OF THE
OMICS YOU ARE GOING TO RUN, I
DON'T KNOW IF THEY ARE ALL
LAST 30 DAYS' EXPOSURE BUT THE
EPIGENETICS EXPOSURE CERTAINLY
ARE NOT SO HOW WILL THOSE
GEOCODED EXPOSURES RELATE TO
EARLY CHILDHOOD EXPOSURES FOR
PEOPLE WHO ARE NOW OLDER?
>>WELL, THAT IS A GREAT
QUESTION.
I WILL ASK Dr. DENG ABOUT
THAT BUT I THINK IT IS THE
LONGITUDINAL STUDY, LOOKING AT
A SNAPSHOT IS NOT PARTICULARLY
USEFUL BUT LOOKING OVER TIME.
WHAT WAS MY MOTHER EXPOSED TO
IN THE 1950S?
A WHOLE BUNCH OF STUFF THAT IS
LIKELY TO BE AFFECTING MY MEN
TAB LIMB AS AN ADULT SO THAT
IS WHERE I AM THINKING WE NEED
TO BE WORKING ON THE
ESPECIALLY ME GENETIC
EXPOSURES.
THINGS I SHOWED FROM MY OWN
LAB.
THE CHANGES THAT HAPPEN AS A
CONSEQUENCE OF APPROACH SURE
DURING PREGNANCY CONTINUE
AFFECTING YOUR METHYLONE MUCH
LATER IN LIFE AND ALSO
DEVELOPING A MORE ROBUST SET
OF BIOMARKERS.
WHAT ARE THE THINGS IN ACAN I
GO DIGS TO ESPECIALLY --
THINGS IN ADDITION TO
EPIGENETIC EXPOSURES TO GET
THAT WINDOW TO ADJUST FOR.
PUT THE OTHER THING I WANT TO
POINT OUT HERE IS THE
CHEMICALS ARE NOT JUST
RELATING TO ROTONOME OR BPA
BUT THINGS THAT AFFECT
ENVIRONMENTA ALMOST JUSTICE.
PSYCHO AND SOCIAL STRESS HAVE
A GREAT AFFECT ON WHETHER WE
ADJUST TO EXPOSURE.
FISH WITH FATTY ACIDS AND
EXPOSED TO AMERICA ROUX IMPACT
CARDIO HEALTH AND BLUEBERRIES
AND BLACKBERRIES CONTAIN THESE
POLYPHENOLS THAT MAY BE
BENEFICIAL.
SO GETTING TO THE BENEFICIAL
HEALTH OF NONCHEMICAL
EXPOSURES HAVE TO BE PART OF
THE EQUATION PUT ALSO I COULD
GIVE A WHOLE LECTURE ON
ENVIRONMENTAL JUSTICE, THOSE
COMMUNITIES OUT THERE WITH
HEALTH DISPARITIES AND THOSE
ARE THE COMMUNITIES WHERE
PEOPLE ARE LIVING IN HOMES
WITH LEAD PAINT, THOSE ARE THE
COMMUNITIES THAT ARE LOCATED
JUST DOWNSTREAM FROM LEAD
SMELTER, COMMUNITIES THAT ARE
I ADJACENT TO THE POWER
PRODUCTION PLANTS SO THERE ARE
ENVIRONMENTAL EXPOSURES THAT
WE NEED TO PAY ATTENTION TO.
DOES THAT ANSWER YOUR
QUESTION?
[LAUGHTER]
AND ALL ENCOMPASSING QUESTION
WITH BPA AND PLASTIC BOTTLES.
ANYTHING ELSE?
>>WE WILL MAKE THIS A REGULAR
UPDATE.
[LAUGHTER]
>>YEAH, SO YOU KNOW WHAT THAT
MEANS, RICHARD, IT MEANS YOU
WILL BE COMING DOWN TO NORTH
CAROLINA WITH SOME REGULARITY.
>>FAIR ENOUGH.
THERE IS A CONNECTION THERE.
>>THANKS AGAIN FOR YOUR
ATTENTION.
>>ALL RIGHT, WELL, THAT
CONCLUDES THEN OUR MAY COUNCIL
MEETING.
I WANT TO AGAIN THANK ALL OUR
COUNCIL MEMBERS FOR ALL THEIR
HARD WORK AND RICH DISCUSSION
WE HAD IN THESE PAST FEW DAYS
AND AGAIN, IT WAS A PLEASURE
SEEING -- LITLY SEEING YOU
DURING THIS TIME TOO.
RICHARD, FINAL WORDS?
>>USE THE GAVEL.
>>BUSINESS ADJOURNED, YES.
[LAUGHTER]